

MAGELLAN HEALTH SERVICES INC  
Form 10-Q  
October 24, 2013

Use these links to rapidly review the document

[TABLE OF CONTENTS](#)

[Table of Contents](#)

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

---

**FORM 10-Q**

(Mark One)

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934**

**For the Quarterly Period Ended September 30, 2013**

Or

**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES  
EXCHANGE ACT OF 1934**

**For the transition period from \_\_\_\_\_ to \_\_\_\_\_  
Commission File No. 1-6639**

**MAGELLAN HEALTH SERVICES, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction of  
incorporation or organization)

**58-1076937**  
(IRS Employer  
Identification No.)

**55 Nod Road, Avon, Connecticut**  
(Address of principal executive offices)

**06001**  
(Zip code)

**(860) 507-1900**  
(Registrant's telephone number, including area code)

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding twelve months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Edgar Filing: MAGELLAN HEALTH SERVICES INC - Form 10-Q

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes  No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, or a non-accelerated filer. See definition of "accelerated filer and large accelerated filer" in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer  Accelerated filer  Non-accelerated filer  Smaller reporting company

(Do not check if a  
smaller reporting company)

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes  No

The number of shares of the registrant's Ordinary Common Stock outstanding as of September 30, 2013 was 27,067,781.

---

Table of Contents

**FORM 10-Q**  
**MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES**  
**INDEX**

		<b>Page No.</b>
<b><u>PART I Financial Information:</u></b>		
<u>Item 1:</u>	<u>Financial Statements</u>	<u>3</u>
	<u>Consolidated Balance Sheets December 31, 2012 and September 30, 2013</u>	<u>3</u>
	<u>Consolidated Statements of Comprehensive Income For the Three Months and Nine Months Ended September 30, 2012 and 2013</u>	<u>4</u>
	<u>Consolidated Statements of Cash Flows For the Nine Months Ended September 30, 2012 and 2013</u>	<u>5</u>
	<u>Notes to Consolidated Financial Statements</u>	<u>6</u>
<u>Item 2:</u>	<u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	<u>26</u>
<u>Item 3:</u>	<u>Quantitative and Qualitative Disclosures about Market Risk</u>	<u>46</u>
<u>Item 4:</u>	<u>Controls and Procedures</u>	<u>46</u>
<b><u>PART II Other Information:</u></b>		
<u>Item 1:</u>	<u>Legal Proceedings</u>	<u>47</u>
<u>Item 1A:</u>	<u>Risk Factors</u>	<u>47</u>
<u>Item 2:</u>	<u>Unregistered Sales of Equity Securities and Use of Proceeds</u>	<u>47</u>
<u>Item 3:</u>	<u>Defaults Upon Senior Securities</u>	<u>48</u>
<u>Item 4:</u>	<u>Mine Safety Disclosures</u>	<u>48</u>
<u>Item 5:</u>	<u>Other Information</u>	<u>48</u>
<u>Item 6:</u>	<u>Exhibits</u>	<u>50</u>
<u>Signatures</u>		<u>51</u>

Table of Contents**PART I FINANCIAL INFORMATION****Item 1. Financial Statements.****MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES****CONSOLIDATED BALANCE SHEETS****(In thousands, except per share amounts)**

	<b>December 31, 2012</b>	<b>September 30, 2013 (unaudited)</b>
<b>ASSETS</b>		
Current Assets:		
Cash and cash equivalents	\$ 189,464	\$ 281,792
Restricted cash	226,554	208,567
Accounts receivable, less allowance for doubtful accounts of \$4,612 and \$4,621 at December 31, 2012 and September 30, 2013, respectively	138,253	157,248
Short-term investments (restricted investments of \$88,332 and \$139,758 at December 31, 2012 and September 30, 2013, respectively)	201,127	212,949
Deferred income taxes	31,698	29,546
Pharmaceutical inventory	45,727	47,407
Other current assets (restricted deposits of \$20,846 and \$26,563 at December 31, 2012 and September 30, 2013, respectively)	38,595	48,244
<b>Total Current Assets</b>	<b>871,418</b>	<b>985,753</b>
Property and equipment, net	136,548	163,552
Long-term investments (restricted investments of \$32,563 and \$14,747 at December 31, 2012 and September 30, 2013, respectively)	32,563	15,629
Other long-term assets	9,730	15,052
Goodwill	426,939	426,939
Other intangible assets, net	34,935	28,072
<b>Total Assets</b>	<b>\$ 1,512,133</b>	<b>\$ 1,634,997</b>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
Current Liabilities:		
Accounts payable	\$ 17,081	\$ 15,930
Accrued liabilities	100,778	107,190
Medical claims payable	198,429	217,290
Other medical liabilities	76,914	74,197
Current maturities of long-term capital lease obligations		2,846
<b>Total Current Liabilities</b>	<b>393,202</b>	<b>417,453</b>
Long-term capital lease obligations		24,167
Deferred income taxes	34,086	32,766
Tax contingencies	60,697	32,846
Deferred credits and other long-term liabilities	6,815	9,036
<b>Total Liabilities</b>	<b>494,800</b>	<b>516,268</b>
Preferred stock, par value \$.01 per share		
Authorized 10,000 shares at December 31, 2012 and September 30, 2013		Issued and outstanding none
Ordinary common stock, par value \$.01 per share		
Authorized 100,000 shares at December 31, 2012 and September 30, 2013		Issued and outstanding 45,928 and 27,353
shares at December 31, 2012, respectively, and 46,599 and 27,068 shares at September 30, 2013, respectively	459	466
Multi-Vote common stock, par value \$.01 per share		
Authorized 40,000 shares		Issued and outstanding none
Other Stockholders' Equity:		

Edgar Filing: MAGELLAN HEALTH SERVICES INC - Form 10-Q

Additional paid-in capital	848,238	890,932
Retained earnings	975,232	1,082,002
Accumulated other comprehensive loss	(35)	(72)
Ordinary common stock in treasury, at cost, 18,575 and 19,531 shares at December 31, 2012 and September 30, 2013, respectively	(806,561)	(854,599)
Total Stockholders' Equity	1,017,333	1,118,729
Total Liabilities and Stockholders' Equity	\$ 1,512,133	\$ 1,634,997

See accompanying notes to consolidated financial statements.

Table of Contents

**MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES**  
**CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME**

(Unaudited)

(In thousands, except per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2012	2013	2012	2013
<b>Net revenue:</b>				
Managed care and other	\$ 711,092	\$ 775,957	\$ 2,114,149	\$ 2,255,748
Dispensing	87,345	97,641	262,974	282,359
<b>Total net revenue</b>	<b>798,437</b>	<b>873,598</b>	<b>2,377,123</b>	<b>2,538,107</b>
<b>Cost and expenses:</b>				
Cost of care	516,238	570,187	1,543,361	1,642,944
Cost of goods sold	81,662	91,853	245,555	265,440
Direct service costs and other operating expenses(1)	135,574	156,834	412,496	440,958
Depreciation and amortization	15,239	17,654	45,172	50,770
Interest expense	537	789	1,713	2,191
Interest income	(350)	(291)	(1,619)	(1,002)
	748,900	837,026	2,246,678	2,401,301
<b>Income before income taxes</b>	<b>49,537</b>	<b>36,572</b>	<b>130,445</b>	<b>136,806</b>
(Benefit) provision for income taxes	(16,725)	(10,660)	16,420	30,036
<b>Net income</b>	<b>66,262</b>	<b>47,232</b>	<b>114,025</b>	<b>106,770</b>
Net income per common share basic (See Note B)	\$ 2.41	\$ 1.75	\$ 4.17	\$ 3.96
Net income per common share diluted (See Note B)	\$ 2.36	\$ 1.70	\$ 4.10	\$ 3.87
<b>Other comprehensive income:</b>				
Unrealized gains (losses) on available-for-sale securities(2)	120	110	208	(37)
<b>Comprehensive income</b>	<b>\$ 66,382</b>	<b>\$ 47,342</b>	<b>\$ 114,233</b>	<b>\$ 106,733</b>

(1) Includes stock compensation expense of \$4,468 and \$4,524 for the three months ended September 30, 2012 and 2013, respectively, and \$13,935 and \$14,764 for the nine months ended September 30, 2012 and 2013, respectively.

(2) Net of income tax provision (benefit) of \$78 and \$74 for the three months ended September 30, 2012 and 2013, respectively, and \$134 and \$(25) for the nine months ended September 30, 2012 and 2013, respectively.

See accompanying notes to consolidated financial statements.



Table of Contents

## MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

## CONSOLIDATED STATEMENTS OF CASH FLOWS

FOR THE NINE MONTHS ENDED SEPTEMBER 30,

(Unaudited)

(In thousands)

	2012	2013
<b>Cash flows from operating activities:</b>		
Net income	\$ 114,025	\$ 106,770
Adjustments to reconcile net income to net cash provided by operating activities:		
Depreciation and amortization	45,172	50,770
Non-cash interest expense	544	552
Non-cash stock compensation expense	13,935	14,764
Non-cash income tax expense (benefit)	12,395	(164)
Non-cash amortization on investments	5,373	7,273
Cash flows from changes in assets and liabilities, net of effects from acquisitions of businesses:		
Restricted cash	(59,777)	17,987
Accounts receivable, net	604	(19,231)
Pharmaceutical inventory	(2,002)	(1,680)
Other assets	(4,218)	(9,781)
Accounts payable and accrued liabilities	(17,854)	6,685
Medical claims payable and other medical liabilities	37,422	16,144
Tax contingencies	(34,616)	(22,981)
Other	654	4,174
Net cash provided by operating activities	111,657	171,282
<b>Cash flows from investing activities:</b>		
Capital expenditures	(53,049)	(42,091)
Purchase of investments	(197,525)	(235,946)
Maturity of investments	215,150	233,723
Other	(7,900)	(7,900)
Net cash used in investing activities	(35,424)	(52,214)
<b>Cash flows from financing activities:</b>		
Payments to acquire treasury stock	(49,462)	(49,462)
Proceeds from exercise of stock options and warrants	13,092	24,548
Payments on capital lease obligations	(2,310)	(2,310)
Other	135	484
Net cash provided by (used in) financing activities	13,227	(26,740)
Net increase in cash and cash equivalents	89,460	92,328
Cash and cash equivalents at beginning of period	119,862	189,464
Cash and cash equivalents at end of period	\$ 209,322	\$ 281,792
<b>Supplemental cash flow data:</b>		
Non-cash investing activities:		
Property and equipment acquired under capital leases	\$	\$ 29,323



See accompanying notes to consolidated financial statements.

Table of Contents

**MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS**

**September 30, 2013**

**(Unaudited)**

**NOTE A General**

***Basis of Presentation***

The accompanying unaudited consolidated financial statements of Magellan Health Services, Inc., a Delaware corporation ("Magellan"), include the accounts of Magellan, its majority owned subsidiaries, and all variable interest entities ("VIEs") for which Magellan is the primary beneficiary (together with Magellan, the "Company"). The financial statements have been prepared in accordance with accounting principles generally accepted in the United States for interim financial information and with the Securities and Exchange Commission's (the "SEC") instructions to Form 10-Q. Accordingly, the financial statements do not include all of the information and footnotes required by accounting principles generally accepted in the United States for complete financial statements. In the opinion of management, all adjustments, consisting of normal recurring adjustments considered necessary for a fair presentation, have been included. The results of operations for the three and nine months ended September 30, 2013 are not necessarily indicative of the results to be expected for the full year. All significant intercompany accounts and transactions have been eliminated in consolidation.

The Company has evaluated subsequent events for recognition or disclosure in the consolidated financial statements filed on this Form 10-Q. Other than as described in Note E "Subsequent Events", the Company did not have any material recognizable subsequent events during this period.

These unaudited consolidated financial statements should be read in conjunction with the Company's audited consolidated financial statements for the year ended December 31, 2012 and the notes thereto, which are included in the Company's Annual Report on Form 10-K filed with the SEC on February 28, 2013.

***Business Overview***

The Company is engaged in the specialty managed healthcare business. Through 2005, the Company predominantly operated in the managed behavioral healthcare business. As a result of certain acquisitions, the Company expanded into radiology benefits management and specialty pharmaceutical management during 2006, and into Medicaid administration during 2009. The Company provides services to health plans, insurance companies, employers, labor unions and various governmental agencies. The Company's business is divided into the following five segments, based on the services it provides and/or the customers that it serves, as described below.

**Managed Behavioral Healthcare**

Two of the Company's segments are in the managed behavioral healthcare business. This line of business generally reflects the Company's coordination and management of the delivery of behavioral healthcare treatment services that are provided through its contracted network of third-party treatment providers, which includes psychiatrists, psychologists, other behavioral health professionals, psychiatric hospitals, general medical facilities with psychiatric beds, residential treatment centers and other treatment facilities. The treatment services provided through the Company's provider network include outpatient programs (such as counseling or therapy), intermediate care programs (such as intensive outpatient programs and partial hospitalization services), inpatient treatment and crisis intervention services. The Company generally does not directly provide or own any provider of treatment services,

Table of Contents

**MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**September 30, 2013**

**(Unaudited)**

**NOTE A General (Continued)**

although it does employ licensed behavioral health counselors to deliver non-medical counseling under certain government contracts.

The Company provides its management services primarily through: (i) risk-based products, where the Company assumes all or a substantial portion of the responsibility for the cost of providing treatment services in exchange for a fixed per member per month fee, (ii) administrative services only ("ASO") products, where the Company provides services such as utilization review, claims administration and/or provider network management, but does not assume responsibility for the cost of the treatment services, and (iii) employee assistance programs ("EAPs") where the Company provides short-term outpatient behavioral counseling services.

The managed behavioral healthcare business is managed based on the services provided and/or the customers served, through the following two segments:

*Commercial.* The Managed Behavioral Healthcare Commercial segment ("Commercial") generally reflects managed behavioral healthcare services and EAP services provided under contracts with health plans and insurance companies for some or all of their commercial, Medicaid and Medicare members, as well as with employers, including corporations, governmental agencies, and labor unions. Commercial's contracts encompass risk-based, ASO and EAP arrangements.

*Public Sector.* The Managed Behavioral Healthcare Public Sector segment ("Public Sector") generally reflects the management of behavioral health services provided to recipients under Medicaid and other state sponsored programs under contracts with state and local governmental agencies. Public Sector contracts also include management services for the integrated physical, behavioral and pharmaceutical care for special populations covered under Medicaid and other government sponsored programs. Public Sector contracts encompass either risk-based or ASO arrangements.

**Radiology Benefits Management**

The Radiology Benefits Management segment ("Radiology Benefits Management") generally reflects the management of the delivery of diagnostic imaging and other therapeutic services to ensure that such services are clinically appropriate and cost effective. The Company's radiology benefits management services currently are provided under contracts with health plans and insurance companies for some or all of their commercial, Medicaid and Medicare members. The Company also contracts with state and local governmental agencies for the provision of such services to Medicaid recipients. The Company offers its radiology benefits management services through risk-based contracts, where the Company assumes all or a substantial portion of the responsibility for the cost of providing diagnostic imaging services, and through ASO contracts, where the Company provides services such as utilization review and claims administration, but does not assume responsibility for the cost of the imaging services.

**Pharmacy Solutions**

The Pharmacy Solutions segment ("Pharmacy Solutions") comprises products and solutions that provide clinical and financial management of drugs paid under medical and pharmacy benefit programs.

Table of Contents

**MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**September 30, 2013**

**(Unaudited)**

**NOTE A General (Continued)**

The Company's Pharmacy Solutions services include (i) pharmacy benefit management ("PBM") programs; (ii) specialty contracting and formulary optimization programs; (iii) specialty pharmaceutical dispensing operations; (iv) medical pharmacy management programs; and (v) programs for the integrated management of drugs that treat complex conditions, regardless of site of service or benefit reimbursement. The Company's pharmacy solutions are provided under contracts with health plans, employers, Medicaid managed care organizations ("MCOs"), state Medicaid programs, and other government agencies, and encompass risk-based and fee-for-service ("FFS") arrangements.

Beginning in the first quarter of 2013, the Company underwent organizational changes. As a result of these changes, the Company concluded that changes to its reportable segments were warranted. This segment contains the operating segments previously defined as the Specialty Pharmaceutical Management segment and the Medicaid Administration segment. Prior period balances have been reclassified to reflect this change.

Corporate

This segment of the Company is comprised primarily of operational support functions such as sales and marketing and information technology, as well as corporate support functions such as executive, finance, human resources and legal.

*Summary of Significant Accounting Policies*

*Recent Accounting Pronouncements*

In October 2012, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2012-04, "Technical Corrections and Improvements" ("ASC 2012-04"). The amendments in this update cover a wide range of Topics in the Accounting Standards Codification. These amendments include technical corrections and improvements to the Accounting Standards Codification and conforming amendments related to fair value measurements. The amendments in this guidance that will not have transition guidance are effective upon issuance. The amendments that are subject to transition guidance are effective for fiscal periods beginning after December 15, 2012 and were adopted by the Company during the quarter ended March 31, 2013. The guidance did not impact the Company's consolidated results of operations, financial position, or cash flows.

In February 2013, the FASB issued ASU No. 2013-02, "Comprehensive Income (Topic 220): Reporting of Amounts Reclassified out of Accumulated Comprehensive Income" ("ASU 2013-02"). ASU 2013-02 requires companies to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required under generally accepted accounting principles ("GAAP") to be reclassified in its entirety to net income. Entities are required to provide information about significant reclassifications by component, and to present those reclassifications either on the face of the statement where net income is presented or in the notes. For other amounts that are not required to be reclassified in their entirety to net income, entities are required to cross-reference other disclosures that provide additional details about those amounts. The amendments in this ASU do not change the current requirements for reporting net income or other comprehensive income in financial statements. The amendments in this

Table of Contents

**MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**September 30, 2013**

**(Unaudited)**

**NOTE A General (Continued)**

ASU are effective prospectively for reporting periods beginning after December 15, 2012 and were adopted by the Company during the quarter ended March 31, 2013. The guidance did not impact the Company's consolidated results of operations, financial position, or cash flows.

In July 2013, the FASB issued ASU No. 2013-11, "Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Carryforward Exists" ("ASU 2013-11"). ASU 2013-11 provides guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability. The amendments in this ASU do not require new recurring disclosures. The amendments in this ASU are effective for reporting periods beginning after December 15, 2013. The guidance is not expected to materially impact the Company's consolidated results of operations, financial position, or cash flows.

*Use of Estimates*

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates of the Company include, among other things, accounts receivable realization, valuation allowances for deferred tax assets, valuation of goodwill and intangible assets, medical claims payable, other medical liabilities, stock compensation assumptions, tax contingencies and legal liabilities. Actual results could differ from those estimates.

*Managed Care and Other Revenue*

*Managed Care Revenue.* Managed care revenue, inclusive of revenue from the Company's risk, EAP and ASO contracts, is recognized over the applicable coverage period on a per member basis for covered members. The Company is paid a per member fee for all enrolled members, and this fee is recorded as revenue in the month in which members are entitled to service. The Company adjusts its revenue for retroactive membership terminations, additions and other changes, when such adjustments are identified, with the exception of retroactivity that can be reasonably estimated. The impact of retroactive rate amendments is generally recorded in the accounting period that terms to the amendment are finalized, and that the amendment is executed. Any fees paid prior to the month of service are recorded as deferred revenue. Managed care revenues approximated \$631.6 million and \$1,871.4 million for the three and nine months ended September 30, 2012, respectively, and \$673.6 million and \$1,957.9 million for the three and nine months ended September 30, 2013, respectively.

*Fee-For-Service and Cost-Plus Contracts.* The Company has certain fee-for-service contracts, including cost-plus contracts, with customers under which the Company recognizes revenue as services

Table of Contents

**MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**September 30, 2013**

**(Unaudited)**

**NOTE A General (Continued)**

are performed and as costs are incurred. Revenues from these contracts approximated \$33.8 million and \$104.8 million for the three and nine months ended September 30, 2012, respectively, and \$52.6 million and \$152.9 million for the three and nine months ended September 30, 2013, respectively.

*Block Grant Revenues.* Public Sector has a contract that is partially funded by federal, state and county block grant money, which represents annual appropriations. The Company recognizes revenue from block grant activity ratably over the period to which the block grant funding applies. Block grant revenues were approximately \$32.6 million and \$90.5 million for the three and nine months ended September 30, 2012, respectively, and \$32.3 million and \$96.9 million for the three and nine months ended September 30, 2013, respectively.

*Performance-Based Revenue.* The Company has the ability to earn performance-based revenue under certain risk and non-risk contracts. Performance-based revenue generally is based on either the ability of the Company to manage care for its clients below specified targets, or on other operating metrics. For each such contract, the Company estimates and records performance-based revenue after considering the relevant contractual terms and the data available for the performance-based revenue calculation. Pro-rata performance-based revenue may be recognized on an interim basis pursuant to the rights and obligations of each party upon termination of the contracts. Performance-based revenues were \$2.6 million and \$14.5 million for the three and nine months ended September 30, 2012, respectively, and \$2.7 million and \$6.1 million for the three and nine months ended September 30, 2013, respectively.

*Rebate Revenue.* The Company administers a rebate program for certain clients through which the Company coordinates the achievement, calculation and collection of rebates and administrative fees from pharmaceutical manufacturers on behalf of clients. Each period, the Company estimates the total rebates earned based on actual volumes of pharmaceutical purchases by the Company's clients, as well as historical and/or anticipated sharing percentages. The Company earns fees based upon the volume of rebates generated for its clients. The Company does not record as rebate revenue any rebates that are passed through to its clients. Total rebate revenues were \$10.3 million and \$29.3 million for the three and nine months ended September 30, 2012, respectively, and \$8.8 million and \$25.6 million for the three and nine months ended September 30, 2013, respectively.

*Dispensing Revenue*

The Company recognizes dispensing revenue, which includes the co-payments received from members of the health plans the Company serves, when the specialty pharmaceutical drugs are shipped. At the time of shipment, the earnings process is complete; the obligation of the Company's customer to pay for the specialty pharmaceutical drugs is fixed, and, due to the nature of the product, the member may neither return the specialty pharmaceutical drugs nor receive a refund. Revenues from the dispensing of specialty pharmaceutical drugs on behalf of health plans were \$87.3 million and \$263.0 million for the three and nine months ended September 30, 2012, respectively, and \$97.6 million and \$282.4 million for the three and nine months ended September 30, 2013, respectively.

Table of Contents

**MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**September 30, 2013**

**(Unaudited)**

**NOTE A General (Continued)**

*Significant Customers*

Consolidated Company

The Company provides behavioral healthcare management and other related services to approximately 685,000 members in Maricopa County, Arizona as the Regional Behavioral Health Authority ("RHBA") for GSA6 ("Maricopa County") pursuant to a contract with the State of Arizona (the "Maricopa Contract").

The Maricopa Contract is for the management of the publicly funded behavioral health system that delivers mental health, substance abuse and crisis services for adults, youth, and children. Under the Maricopa Contract, the Company is responsible for providing covered behavioral health services to persons eligible under Title XIX (Medicaid) and Title XXI (State Children's Health Insurance Program) of the Social Security Act, non-Title XIX and non-Title XXI eligible children and adults with a serious mental illness, and to certain non-Title XIX and non-Title XXI adults with behavioral health or substance abuse disorders. The Maricopa Contract began on September 1, 2007 and was scheduled to expire on October 1, 2013. The Company and the State of Arizona have agreed to extend the Maricopa Contract through March 31, 2014. The State of Arizona has the right to terminate the Maricopa Contract for cause, as defined, upon ten days' notice with an opportunity to cure, and, after January 1, 2014, without cause upon 30 days prior notice to the Company. The Maricopa Contract generated net revenues of \$566.2 million and \$557.6 million for the nine months ended September 30, 2012 and 2013, respectively.

The State of Arizona had previously issued a Solicitation for a new RBHA for Maricopa County (the "New Contract") to replace the current contract with the Company to be effective on October 1, 2013. The New Contract is for the management of the publicly funded behavioral health system currently provided by the Company under the Maricopa Contract, and also includes an integrated behavioral and physical health care system for a small number of individuals with serious mental illness. Magellan Complete Care of Arizona, a joint venture owned 80% by the Company and 20% by Vanguard/Phoenix Health Plan, previously submitted a bid for the Contract.

On March 25, 2013, the Company was notified that Magellan Complete Care of Arizona was not selected as the RBHA for the New Contract. On April 3, 2013, the Company filed a formal protest regarding the State's decision to award the RBHA in Maricopa County to another vendor. On April 17, 2013, the Arizona Department of Health Services denied the Company's protest. On May 9, 2013, the Company filed an appeal of the denial of its protest (the "Appeal") with the Arizona Department of Administration (the "DOA"), the agency responsible for considering appeals of procurement protest denials. The Company also filed with the DOA a motion to stay the award and implementation of the contract pending a decision on the Appeal. On May 21, 2013, the DOA granted the Company's motion and issued a stay of the award and implementation of the contract pending resolution of the Appeal by the DOA (the "Stay").

Table of Contents

## MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2013

(Unaudited)

**NOTE A General (Continued)**

On June 13, 2013 the DOA referred the Appeal for a hearing before an independent administrative law judge in the Arizona Office of Administrative Hearings (the "OAH"). The OAH held an evidentiary hearing on the Appeal on September 18-27, 2013. Post-hearing briefing will be completed by October 29, 2013 and the Company anticipates the administrative law judge will issue her decision and recommendation to DOA on or before November 18, 2013. The DOA will then have 30 days to review the administrative law judge's decision and recommendation and issue its decision on Magellan's appeal of the protest denial. There is no assurance that the Company will prevail on the Appeal or that the Stay will remain in effect.

*By Segment*

In addition to the Maricopa Contract previously discussed, the following customers generated in excess of ten percent of net revenues for the respective segment for the nine months ended September 30, 2012 and 2013 (in thousands):

Segment	Term Date	2012	2013
<b>Commercial</b>			
Customer A	Mid-2014(1)	\$ 144,499	\$ 156,269
Customer B	December 31, 2019	101,249	106,433
Customer C	December 31, 2012 to December 14, 2013(2)(3)	89,592	58,246
<b>Public Sector</b>			
Customer D	June 30, 2014(4)	175,440	209,266
<b>Radiology Benefits Management</b>			
Customer E	December 31, 2015	83,158	96,402
Customer F	June 30, 2014	44,959	43,490
Customer G	July 31, 2015	42,458	47,161
Customer H	January 31, 2014	27,824	34,338
<b>Pharmacy Solutions</b>			
Customer I	November 30, 2013 to December 31, 2013(2)	98,128	99,599
Customer J	December 31, 2013(5)	45,018	43,315*
Customer K	December 31, 2013(5)	53,640	68,166
Customer L	September 30, 2013(6)	53,259	48,527

\*

Revenue amount did not exceed ten percent of net revenues for the respective segment for the period presented. Amount is shown for comparative purposes only.

(1)

The customer has informed the Company that, after a competitive evaluation process, it has decided not to renew its contract after the contract expires on December 31, 2013. The Company anticipates the contract will extend through mid-2014 to allow for transition to new vendor.

(2)

The customer has more than one contract. The individual contracts are scheduled to terminate at various points during the time period indicated above.





Table of Contents

**MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**September 30, 2013**

**(Unaudited)**

**NOTE A General (Continued)**

- (3) Revenues for the nine months ended September 30, 2012 of \$38.0 million relate to a contract that terminated as of December 31, 2012. The customer has informed the Company that it has decided not to renew the remaining contract after the contract expires on December 14, 2013.
- (4) Contract has options for the customer to extend the term for two additional one-year periods.
- (5) The Company has received notification that the customer will not renew its contracts for specialty pharmacy and related services. The Company has multiple contracts that are currently scheduled to terminate on December 31, 2013.
- (6) This customer represents a subcontract with a Public Sector customer and is eliminated in consolidation.

*Concentration of Business*

The Company also has a significant concentration of business with various counties in the State of Pennsylvania (the "Pennsylvania Counties") which are part of the Pennsylvania Medicaid program, and with various areas in the State of Florida (the "Florida Areas") which are part of the Florida Medicaid program. Net revenues from the Pennsylvania Counties in the aggregate totaled \$269.8 million and \$269.1 million for the nine months ended September 30, 2012 and 2013, respectively. Net revenues from the Florida Areas in the aggregate totaled \$100.6 million and \$97.8 million for the nine months ended September 30, 2012 and 2013, respectively.

The Company's contracts with customers typically have terms of one to three years, and in certain cases contain renewal provisions (at the customer's option) for successive terms of between one and two years (unless terminated earlier). Substantially all of these contracts may be immediately terminated with cause and many of the Company's contracts are terminable without cause by the customer or the Company either upon the giving of requisite notice and the passage of a specified period of time (typically between 60 and 180 days) or upon the occurrence of other specified events. In addition, the Company's contracts with federal, state and local governmental agencies generally are conditioned on legislative appropriations. These contracts generally can be terminated or modified by the customer if such appropriations are not made.

*Fair Value Measurements*

The Company currently does not have non-financial assets and non-financial liabilities that are required to be measured at fair value on a recurring basis. Financial assets and liabilities are to be measured using inputs from the three levels of the fair value hierarchy, which are as follows:

Level 1 Inputs are unadjusted quoted prices in active markets for identical assets or liabilities that the Company has the ability to access at the measurement date.

Level 2 Inputs include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets or liabilities in markets that are not active, inputs other than quoted prices that are observable for the asset or liability (i.e., interest rates, yield curves,

Table of Contents

## MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2013

(Unaudited)

**NOTE A General (Continued)**

etc.), and inputs that are derived principally from or corroborated by observable market data by correlation or other means (market corroborated inputs).

Level 3 Unobservable inputs that reflect the Company's assumptions about the assumptions that market participants would use in pricing the asset or liability. The Company develops these inputs based on the best information available, including the Company's data.

In accordance with the fair value hierarchy described above, the following table shows the fair value of the Company's financial assets and liabilities that are required to be measured at fair value as of December 31, 2012 and September 30, 2013 (in thousands):

	December 31, 2012			Total
	Level 1	Level 2	Level 3	
Cash and cash equivalents(1)	\$	\$ 102,137	\$	\$ 102,137
Restricted cash(2)		82,839		82,839
Investments:				
U.S. government and agency securities	1,065			1,065
Obligations of government-sponsored enterprises(3)		6,128		6,128
Corporate debt securities		214,547		214,547
Taxable municipal bonds		11,800		11,800
Certificates of deposit		150		150
December 31, 2012	\$ 1,065	\$ 417,601	\$	\$ 418,666

	September 30, 2013			Total
	Level 1	Level 2	Level 3	
Cash and cash equivalents(4)	\$	\$ 75,861	\$	\$ 75,861
Restricted cash(5)		117,611		117,611
Investments:				
U.S. government and agency securities	1,130			1,130
Obligations of government-sponsored enterprises(3)		8,410		8,410
Corporate debt securities		218,288		218,288
Taxable municipal bonds		600		600
Certificates of deposit		150		150
September 30, 2013	\$ 1,130	\$ 420,920	\$	\$ 422,050

(1) Excludes \$87.3 million of cash held in bank accounts by the Company.

(2)

Edgar Filing: MAGELLAN HEALTH SERVICES INC - Form 10-Q

Excludes \$143.7 million of restricted cash held in bank accounts by the Company.

(3)

Includes investments in notes issued by the Federal Home Loan Bank.

(4)

Excludes \$205.9 million of cash held in bank accounts by the Company.

Table of Contents

## MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2013

(Unaudited)

**NOTE A General (Continued)**

(5)

Excludes \$91.0 million of restricted cash held in bank accounts by the Company.

For the nine months ended September 30, 2013, the Company has not transferred any assets between fair value measurement levels.

All of the Company's investments are classified as "available-for-sale" and are carried at fair value.

If a debt security is in an unrealized loss position and the Company has the intent to sell the debt security, or it is more likely than not that the Company will have to sell the debt security before recovery of its amortized cost basis, the decline in value is deemed to be other-than-temporary and is recorded to other-than-temporary impairment losses recognized in income in the consolidated statements of comprehensive income. For impaired debt securities that the Company does not intend to sell or it is more likely than not that the Company will not have to sell such securities, but the Company expects that it will not fully recover the amortized cost basis, the credit component of the other-than-temporary impairment is recognized in other-than-temporary impairment losses recognized in income in the consolidated statements of comprehensive income and the non-credit component of the other-than-temporary impairment is recognized in other comprehensive income.

As of December 31, 2012 and September 30, 2013, there were no unrealized losses that the Company believed to be other-than-temporary. No realized gains or losses were recorded for the nine months ended September 30, 2012 or 2013. The following is a summary of short-term and long-term investments at December 31, 2012 and September 30, 2013 (in thousands):

	Amortized Cost	December 31, 2012		Estimated Fair Value
		Gross Unrealized Gains	Gross Unrealized Losses	
U.S. government and agency securities	\$ 1,065	\$	\$	\$ 1,065
Obligations of government-sponsored enterprises(1)	6,126	4	(2)	6,128
Corporate debt securities	214,603	66	(122)	214,547
Taxable municipal bonds	11,805		(5)	11,800
Certificates of deposit	150			150
Total investments at December 31, 2012	\$ 233,749	\$ 70	\$ (129)	\$ 233,690

Table of Contents

## MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2013

(Unaudited)

## NOTE A General (Continued)

	Amortized Cost	September 30, 2013		Estimated Fair Value
		Gross Unrealized Gains	Gross Unrealized Losses	
U.S. government and agency securities	\$ 1,130	\$	\$	\$ 1,130
Obligations of government-sponsored enterprises(1)	8,408	3	(1)	8,410
Corporate debt securities	218,411	28	(151)	218,288
Taxable municipal bonds	600			600
Certificates of deposit	150			150
Total investments at September 30, 2013	\$ 228,699	\$ 31	\$ (152)	\$ 228,578

(1)

Includes investments in notes issued by the Federal Home Loan Bank.

The maturity dates of the Company's investments as of September 30, 2013 are summarized below (in thousands):

	Amortized Cost	Estimated Fair Value
2013	\$ 99,253	\$ 99,211
2014	121,593	121,522
2015	7,853	7,845
Total investments at September 30, 2013	\$ 228,699	\$ 228,578

*Note Receivable and Preferred Stock*

The Company holds a 7% equity interest in AlphaCare of New York, Inc. ("AlphaCare") through an equity investment of \$2.0 million in preferred membership units of AlphaCare's current holding company, AlphaCare Holdings, LLC on May 17, 2013. During the current year, the Company also loaned \$5.9 million to AlphaCare Holdings, LLC pursuant to a promissory note (the "Note") which was secured by a pledge of all of the outstanding stock of AlphaCare. AlphaCare is a newly licensed HMO in New York that operates a New York Managed Long-Term Care Plan ("MLTCP") in Bronx, New York, Queens, Kings and Westchester Counties, and Medicare Plans in Bronx, New York, Queens and Kings Counties.

On August 13, 2013, the Company entered into a stock purchase agreement (the "Stock Purchase Agreement") under which it agreed to acquire a 65% equity interest in AlphaCare through an investment in its holding company.

As contemplated by the Stock Purchase Agreement, AlphaCare Holdings, LLC will merge with and into AlphaCare Holdings, Inc. ("AlphaCare Holdings"), a recently-formed Delaware holding corporation, and the Company's 7% equity interest and the Note will be converted into shares of Series A Participating Preferred Stock ("Series A Preferred") of AlphaCare Holdings. The Company will also purchase additional shares of Series A Preferred stock such that it will own 65% of the outstanding shares of AlphaCare Holdings for an aggregate acquisition price

of \$25.5 million, including its original investment of \$7.9 million.

Table of Contents

**MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**September 30, 2013**

**(Unaudited)**

**NOTE A General (Continued)**

The closing of the Stock Purchase Agreement is subject to various conditions, including approval of the New York State Department of Health. The Company expects that the closing of the Stock Purchase Agreement will occur in late 2013 or early 2014.

*Income Taxes*

The Company's effective income tax rates were 12.6 percent and 22.0 percent for the nine months ended September 30, 2012 and 2013, respectively. These rates differ from the federal statutory income tax rate primarily due to state income taxes, permanent differences between book and tax income, and changes to recorded tax contingencies. The Company also accrues interest and penalties related to unrecognized tax benefits in its provision for income taxes. The effective income tax rate for the nine months ended September 30, 2012 is lower than the effective rate for the nine months ended September 30, 2013 mainly due to lower reversals of tax contingencies in the current year from the closure of statutes of limitation.

The Company files a consolidated federal income tax return for the Company and its eighty percent or more owned subsidiaries, and the Company and its subsidiaries file income tax returns in various states and local jurisdictions. With few exceptions, the Company is no longer subject to state or local income tax assessments by tax authorities for years ended prior to 2009. Further, the statutes of limitation regarding the assessment of federal and certain state and local income taxes for 2009 closed during the current quarter. As a result, \$27.2 million of unrecognized tax benefits (excluding interest costs) recorded as of December 31, 2012 were reversed in the current quarter, of which \$22.7 million is reflected as a discrete reduction to income tax expense, \$3.9 million as an increase to additional paid-in capital, and the remainder as a decrease to deferred tax assets. Additionally, \$2.1 million of accrued interest was reversed in the current quarter and reflected as a reduction to income tax expense due to the closing of statutes of limitation on tax assessments.

*Stock Compensation*

At December 31, 2012 and September 30, 2013, the Company had equity-based employee incentive plans, which are described more fully in Note 6 in the Company's Annual Report on Form 10-K for the year ended December 31, 2012. The Company recorded stock compensation expense of \$4.5 million and \$13.9 million for the three and nine months ended September 30, 2012, respectively, and \$4.5 million and \$14.8 million for the three and nine months ended September 30, 2013, respectively. Stock compensation expense recognized in the consolidated statements of comprehensive income for the three and nine months ended September 30, 2012 and 2013 has been reduced for estimated forfeitures, estimated at four percent for both periods.

The weighted average grant date fair value of all stock options granted during the nine months ended September 30, 2013 was \$12.10 as estimated using the Black-Scholes-Merton option pricing model, which also assumed an expected volatility of 27.86 percent based on the historical volatility of the Company's stock price.

The benefits of tax deductions in excess of recognized stock compensation expense are reported as a financing cash flow, rather than as an operating cash flow. In the nine months ended September 30,



Table of Contents

## MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2013

(Unaudited)

**NOTE A General (Continued)**

2012 and 2013, \$0.9 million and \$1.1 million, respectively, of benefits of such tax deductions related to stock compensation expense were realized and as such were reported as financing cash flows. For the nine months ended September 30, 2012 the net change to additional paid in capital related to tax benefits (deficiencies) was \$0.6 million, which includes the \$0.9 million of excess tax benefits offset by \$(0.3) million of tax deficiencies. For the nine months ended September 30, 2013, the net change to additional paid in capital related to tax benefits (deficiencies) was \$0.4 million, which includes the \$1.1 million of excess tax benefits offset by \$(0.7) million of excess tax deficiencies.

Summarized information related to the Company's stock options for the nine months ended September 30, 2013 is as follows:

	Options	Weighted Average Exercise Price
Outstanding, beginning of period	4,268,240	\$ 44.35
Granted	981,133	52.65
Forfeited	(101,476)	49.02
Exercised	(562,554)	43.22
Outstanding, end of period	4,585,343	\$ 46.16
Vested and expected to vest at end of period	4,538,122	\$ 46.11
Exercisable, end of period	2,519,497	\$ 42.84

With the exception of options granted to the Company's CEO, generally all of the Company's options granted during the nine months ended September 30, 2013 vest ratably on each anniversary date over the three years subsequent to grant. During the nine months ended September 30, 2013, the Company granted options to the Company's CEO which vest over four year annual installments, with 16.7 percent, 33.3 percent, 33.3 percent, and 16.7 percent vesting in 2014, 2015, 2016, and 2017, respectively. All options granted during the nine months ended September 30, 2013 have a ten year life.

Summarized information related to the Company's nonvested restricted stock awards for the nine months ended September 30, 2013 is as follows:

	Shares	Weighted Average Grant Date Fair Value
Outstanding, beginning of period	23,672	\$ 42.25
Awarded	16,569	52.82
Vested	(23,672)	42.25
Forfeited		
Outstanding, ending of period	16,569	\$ 52.82

Table of Contents**MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****September 30, 2013****(Unaudited)****NOTE A General (Continued)**

Summarized information related to the Company's nonvested restricted stock units for the nine months ended September 30, 2013 is as follows:

	Shares	Weighted Average Grant Date Fair Value
Outstanding, beginning of period	202,690	\$ 47.38
Awarded	98,580	52.62
Vested	(95,138)	46.72
Forfeited	(5,935)	49.39
Outstanding, ending of period	200,197	\$ 50.21

Grants of restricted stock awards vest on the anniversary of the grant. With the exception of restricted stock units awarded to the Company's CEO during the nine months ended September 30, 2013, generally all of the Company's restricted stock units vest ratably on each anniversary over the three years subsequent to grant, assuming that the associated performance hurdle(s) for that vesting year are met. During the nine months ended September 30, 2013, the Company granted restricted stock units to the Company's CEO which vest over four year annual installments, with 16.7 percent, 33.3 percent, 33.3 percent, and 16.7 percent vesting in 2014, 2015, 2016, and 2017, respectively, assuming the associated performance hurdle(s) for that vesting year are met.

*Long Term Debt and Capital Lease Obligations*

On December 9, 2011, the Company entered into a Senior Secured Revolving Credit Facility Credit Agreement with Citibank, N.A., Wells Fargo Bank, N.A., Bank of America, N.A., and U.S. Bank, N.A. that provides for up to \$230.0 million of revolving loans with a sublimit of up to \$70.0 million for the issuance of letters of credit for the account of the Company (the "2011 Credit Facility"). Citibank, N.A., has assigned a portion of its interest in the 2011 Credit Facility to Bank of Tokyo. The 2011 Credit Facility is guaranteed by substantially all of the subsidiaries of the Company and is secured by substantially all of the assets of the Company and the subsidiary guarantors. The 2011 Credit Facility will mature on December 9, 2014.

Under the 2011 Credit Facility, the annual interest rate on revolving loan borrowings is equal to (i) in the case of U.S. dollar denominated loans, the sum of a borrowing margin of 0.75 percent plus the higher of the prime rate, one-half of one percent in excess of the overnight "federal funds" rate, or the Eurodollar rate for one month plus 1.00 percent, or (ii) in the case of Eurodollar denominated loans, the sum of a borrowing margin of 1.75 percent plus the Eurodollar rate for the selected interest period. The Company has the option to borrow in U.S. dollar denominated loans or Eurodollar denominated loans at its discretion. Letters of credit issued under the Revolving Loan Commitment bear interest at the rate of 1.875 percent. The commitment commission on the 2011 Credit Facility is 0.375 percent of the unused Revolving Loan Commitment.

Table of Contents**MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****September 30, 2013****(Unaudited)****NOTE A General (Continued)**

There were no capital lease obligations at December 31, 2012 and \$27.0 million of capital lease obligations at September 30, 2013. The Company had \$32.0 million and \$32.4 million of letters of credit outstanding at December 31, 2012 and September 30, 2013, respectively, and no revolving loan borrowings at December 31, 2012 or September 30, 2013.

*Reclassifications*

Certain prior year amounts have been reclassified to conform with the current year presentation.

**NOTE B Net Income per Common Share**

The following tables reconcile income (numerator) and shares (denominator) used in the computations of net income per common share (in thousands, except per share data):

	<b>Three Months Ended September 30,</b>		<b>Nine Months Ended September 30,</b>	
	<b>2012</b>	<b>2013</b>	<b>2012</b>	<b>2013</b>
<b>Numerator:</b>				
Net income	\$ 66,262	\$ 47,232	\$ 114,025	\$ 106,770
<b>Denominator:</b>				
Weighted average number of common shares outstanding basic	27,521	26,990	27,346	26,976
Common stock equivalents stock options	426	655	395	539
Common stock equivalents restricted stock	7	4	10	11
Common stock equivalents restricted stock units	87	54	83	35
Common stock equivalents employee stock purchase plan	1	1	1	2
<b>Weighted average number of common shares outstanding diluted</b>	<b>28,042</b>	<b>27,704</b>	<b>27,835</b>	<b>27,563</b>
Net income per common share basic	\$ 2.41	\$ 1.75	\$ 4.17	\$ 3.96
<b>Net income per common share diluted</b>	<b>\$ 2.36</b>	<b>\$ 1.70</b>	<b>\$ 4.10</b>	<b>\$ 3.87</b>

The weighted average number of common shares outstanding for the three and nine months ended September 30, 2012 and 2013 were calculated using outstanding shares of the Company's common stock. Common stock equivalents included in the calculation of diluted weighted average common shares outstanding for the three and nine months ended September 30, 2012 and 2013 represent stock options to purchase shares of the Company's common stock, restricted stock awards and restricted stock units, and stock purchased under the Employee Stock Purchase Plan.

The Company had additional potential dilutive securities outstanding representing 2.3 million and 2.2 million options for the three and nine months ended September 30, 2012, respectively, and 0.9 million and 0.9 million for the three and nine months ended September 30, 2013, respectively, that were not included in the computation of dilutive securities because they were anti-dilutive for the

Table of Contents**MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES****NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)****September 30, 2013****(Unaudited)****NOTE B Net Income per Common Share (Continued)**

period. Had these shares not been anti-dilutive, all of these shares would not have been included in the net income per common share calculation as the Company uses the treasury stock method of calculating diluted shares.

**NOTE C Business Segment Information**

The accounting policies of the Company's segments are the same as those described in Note A "General." The Company evaluates performance of its segments based on income before income taxes, before stock compensation expense, depreciation and amortization, interest expense, interest income, gain on sale of assets, and special charges or benefits ("Segment Profit"). Management uses Segment Profit information for internal reporting and control purposes and considers it important in making decisions regarding the allocation of capital and other resources, risk assessment and employee compensation, among other matters. Effective September 1, 2010, Public Sector has subcontracted with Pharmacy Solutions to provide pharmacy benefits management services on a risk basis for one of Public Sector's customers. As such, revenue and cost of care related to this intersegment arrangement are eliminated. The Company's segments are defined above. The Pharmacy Solutions segment contains the operating segments previously defined as the Specialty Pharmaceutical Management segment and the Medicaid Administration segment. Prior period balances have been reclassified to reflect this change.

The following tables summarize, for the periods indicated, operating results by business segment (in thousands):

	Commercial	Public Sector	Radiology Benefits Management	Pharmacy Solutions	Corporate and Elimination	Consolidated
<b>Three Months Ended September 30, 2012</b>						
Managed care and other revenue	\$ 176,713	\$ 407,265	\$ 88,126	\$ 54,421	\$ (15,433)	\$ 711,092
Dispensing revenue				87,345		87,345
Cost of care	(100,973)	(358,959)	(58,080)	(13,659)	15,433	(516,238)
Cost of goods sold				(81,662)		(81,662)
Direct service costs and other	(43,007)	(22,948)	(14,045)	(27,565)	(28,009)	(135,574)
Stock compensation expense(1)	293	278	419	238	3,240	4,468
Segment profit (loss)	\$ 33,026	\$ 25,636	\$ 16,420	\$ 19,118	\$ (24,769)	\$ 69,431

Table of Contents

## MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2013

(Unaudited)

## NOTE C Business Segment Information (Continued)

	Commercial	Public Sector	Radiology Benefits Management	Pharmacy Solutions	Corporate and Elimination	Consolidated
<b>Three Months Ended September 30, 2013</b>						
Managed care and other revenue	\$ 190,655	\$ 445,260	\$ 94,125	\$ 63,008	\$ (17,091)	\$ 775,957
Dispensing revenue				97,641		97,641
Cost of care	(118,022)	(382,913)	(65,403)	(20,940)	17,091	(570,187)
Cost of goods sold				(91,853)		(91,853)
Direct service costs and other	(47,032)	(27,826)	(13,990)	(32,281)	(35,705)	(156,834)
Stock compensation expense(1)	124	259	384	198	3,559	4,524
Segment profit (loss)	\$ 25,725	\$ 34,780	\$ 15,116	\$ 15,773	\$ (32,146)	\$ 59,248

	Commercial	Public Sector	Radiology Benefits Management	Pharmacy Solutions	Corporate and Elimination	Consolidated
<b>Nine Months Ended September 30, 2012</b>						
Managed care and other revenue	\$ 535,464	\$ 1,206,289	\$ 253,809	\$ 171,846	\$ (53,259)	\$ 2,114,149
Dispensing revenue				262,974		262,974
Cost of care	(323,992)	(1,058,384)	(166,364)	(47,880)	53,259	(1,543,361)
Cost of goods sold				(245,555)		(245,555)
Direct service costs and other	(127,825)	(66,850)	(41,113)	(83,532)	(93,176)	(412,496)
Stock compensation expense(1)	830	835	1,179	704	10,387	13,935
Segment profit (loss)	\$ 84,477	\$ 81,890	\$ 47,511	\$ 58,557	\$ (82,789)	\$ 189,646

Table of Contents

## MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES

## NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)

September 30, 2013

(Unaudited)

## NOTE C Business Segment Information (Continued)

	Commercial	Public Sector	Radiology Benefits Management	Pharmacy Solutions	Corporate and Elimination	Consolidated
<b>Nine Months Ended September 30, 2013</b>						
Managed care and other revenue	\$ 578,030	\$ 1,266,739	\$ 277,118	\$ 182,418	\$ (48,557)	\$ 2,255,748
Dispensing revenue				282,359		282,359
Cost of care	(354,520)	(1,095,694)	(182,212)	(59,075)	48,557	(1,642,944)
Cost of goods sold				(265,440)		(265,440)
Direct service costs and other	(129,823)	(82,403)	(41,224)	(93,216)	(94,292)	(440,958)
Stock compensation expense(1)	390	833	1,275	898	11,368	14,764
Segment profit (loss)	\$ 94,077	\$ 89,475	\$ 54,957	\$ 47,944	\$ (82,924)	\$ 203,529

(1)

Stock compensation expense is included in direct service costs and other operating expenses, however this amount is excluded from the computation of Segment Profit since it is managed on a consolidated basis.

The following table reconciles Segment Profit to income before income taxes (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2012	2013	2012	2013
Segment profit	\$ 69,431	\$ 59,248	\$ 189,646	\$ 203,529
Stock compensation expense	(4,468)	(4,524)	(13,935)	(14,764)
Depreciation and amortization	(15,239)	(17,654)	(45,172)	(50,770)
Interest expense	(537)	(789)	(1,713)	(2,191)
Interest income	350	291	1,619	1,002
Income before income taxes	\$ 49,537	\$ 36,572	\$ 130,445	\$ 136,806

## NOTE D Commitments and Contingencies

*Legal*

The management and administration of the delivery of specialty managed healthcare entails significant risks of liability. From time to time, the Company is subject to various actions and claims arising from the acts or omissions of its employees, network providers or other parties. In the normal course of business, the Company receives reports relating to deaths and other serious incidents involving patients whose care is being managed by the Company. Such incidents occasionally give rise to malpractice, professional negligence and other related actions and claims against the Company or its



Table of Contents

**MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**September 30, 2013**

**(Unaudited)**

**NOTE D Commitments and Contingencies (Continued)**

network providers. Many of these actions and claims received by the Company seek substantial damages and therefore require the Company to incur significant fees and costs related to their defense.

On July 25, 2012, the Company filed a lawsuit currently pending in the United States District Court for the District of Connecticut against two former employees and a corporation partially-owned by one of such former employees asserting claims for violation of contractual restrictive covenants and common law obligations owed to the Company arising from actions of such former employees in connection with their employment by the defendant corporation. The Company's complaint alleges claims for breach of contract and breach of the covenant of good dealing against the individual former employees; tortious interference with contract against the defendant corporation; and violation of the Connecticut Uniform Trade Secrets Act, civil conspiracy, and violation of the Connecticut Unfair Trade Practices Act against all defendants arising out of activity undertaken by the former employees on behalf of the defendant corporation in competition with the Company's specialty pharmacy business. The Company is seeking a permanent injunction and recovery of compensatory and punitive damages and an award of attorneys' fees and costs. On December 18, 2012, the defendant corporation filed counterclaims against the Company in which it asserts tortious interference with business expectancy, abuse of process, and violation of the Connecticut Unfair Trade Practices Act arising out of the Company's efforts to enforce its contractual and legal rights. On June 10, 2013, the defendant corporation disclosed an alleged damages computation in the amount of \$155 million in lost profits plus unspecified business diminution damages. The Company believes the counterclaims and damages calculations of the defendant corporation are without merit and is defending them vigorously.

The Company is also subject to or party to certain class actions and other litigation and claims relating to its operations or business practices. In the opinion of management, the Company has recorded reserves that are adequate to cover litigation, claims or assessments that have been or may be asserted against the Company, and for which the outcome is probable and reasonably estimable. Management believes that the resolution of such litigation and claims will not have a material adverse effect on the Company's financial condition or results of operations; however, there can be no assurance in this regard.

*Stock Repurchases*

On October 25, 2011 the Company's board of directors approved a stock repurchase plan which authorized the Company to purchase up to \$200 million of its outstanding common stock through October 25, 2013. On July 24, 2013 the Company's board of directors approved an increase and extension of the stock repurchase plan which authorizes the Company to purchase up to \$300 million of its outstanding stock through October 25, 2015.

Stock repurchases under the program may be purchased from time to time in open market transactions (including blocks) or in privately negotiated transactions. The timing of repurchases and the actual amount purchased will depend on a variety of factors including the market price of the Company's shares, general market and economic conditions, and other corporate considerations. Repurchases may be made pursuant to plans intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, which could allow the Company to purchase its shares during periods when it



Table of Contents

**MAGELLAN HEALTH SERVICES, INC. AND SUBSIDIARIES**

**NOTES TO CONSOLIDATED FINANCIAL STATEMENTS (Continued)**

**September 30, 2013**

**(Unaudited)**

**NOTE D Commitments and Contingencies (Continued)**

otherwise might be prevented from doing so under insider trading laws or because of self-imposed trading blackout periods. Repurchases are expected to be funded from working capital and anticipated cash from operations. The repurchase authorization does not require the purchase of a specific number of shares and is subject to suspension or termination by the Company's board of directors at any time. Pursuant to this program, the Company made open market purchases of 671,776 shares of the Company's common stock at an average price of \$48.72 per share for an aggregate cost of \$32.7 million (excluding broker commissions) during the period from November 11, 2011 through December 31, 2011. Pursuant to this program, the Company made open market purchases of 459,252 shares of the Company's common stock at an average price of \$50.27 per share for an aggregate cost of \$23.1 million (excluding broker commissions) during 2012. Pursuant to this program, the Company made open market purchases of 955,776 shares of the Company's common stock at an average price of \$50.23 per share for an aggregate cost of \$48.0 million (excluding broker commissions) during the nine months ended September 30, 2013. As of September 30, 2013, the total dollar value remaining under the current authorization was \$196.2 million.

The Company made no open market purchases for the period from October 1, 2013 through October 21, 2013.

**NOTE E Subsequent Events**

*Acquisition of Partners Rx Management LLC*

Pursuant to the September 6, 2013 Agreement and Plan of Merger (the "Merger Agreement") with Partners Rx Management, LLC ("Partners Rx"), on October 1, 2013 the Company acquired (the "Acquisition") all of the outstanding ownership interests of Partners Rx. Partners Rx is a privately held, full-service commercial PBM with a strong focus on health plans and self-funded employers primarily through sales through third party administrators ("TPAs"), consultants and brokers. As consideration for the Acquisition, the Company paid \$100 million in cash, subject to working capital adjustments. The Company funded the Acquisition with cash on hand.

Pursuant to the Merger Agreement, certain principal owners of Partners Rx purchased a total of \$10 million in the Company's restricted stock at a price equal to the average of the closing prices of the Company's stock for the five trading day period ended on the day prior to the execution of the Merger Agreement. The shares received by such principal owners of Partners Rx are subject to vesting over three years with 50% vesting on the second anniversary of the Acquisition and 50% vesting on the third anniversary of the Acquisition, conditioned on continued employment with the Company on the applicable vesting dates.

The Company will report the results of Partners Rx within its Pharmacy Solutions segment.

Table of Contents

**Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations.**

The following discussion and analysis of the financial condition and results of operations of Magellan and its majority-owned subsidiaries and all VIEs for which Magellan is the primary beneficiary should be read together with the Consolidated Financial Statements and the notes to the Consolidated Financial Statements included elsewhere in this Quarterly Report on Form 10-Q and the Company's Annual Report on Form 10-K for the year ended December 31, 2012, which was filed with the SEC on February 28, 2013.

*Forward-Looking Statements*

This Form 10-Q includes "forward-looking statements" within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. Although the Company believes that its plans, intentions and expectations as reflected in such forward-looking statements are reasonable, it can give no assurance that such plans, intentions or expectations will be achieved. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. Important factors currently known to management that could cause actual results to differ materially from those in forward-looking statements include:

the Company's inability to renegotiate or extend expiring customer contracts, or the termination of customer contracts;

the Company's inability to integrate acquisitions in a timely and effective manner;

changes in business practices of the industry, including the possibility that certain of the Company's managed care customers could seek to provide managed healthcare services directly to their subscribers, instead of contracting with the Company for such services, particularly as a result of further consolidation in the managed care industry and especially regarding managed healthcare customers that have already done so with a portion of their membership;

the impact of changes in the contracting model for Medicaid contracts, including certain changes in the contracting model used by states for managed healthcare services contracts relating to Medicaid lives;

the Company's ability to accurately predict and control healthcare costs, and to properly price the Company's services;

the Company's ability to accurately underwrite and control healthcare costs associated with its expansion into clinically integrated management of special populations eligible for Medicaid and Medicare, including individuals with serious mental illness and other unique high-cost populations;

the Company's ability to maintain or secure cost-effective healthcare provider contracts;

fluctuation in quarterly operating results due to seasonal and other factors;

the Company's dependence on government spending for managed healthcare, including changes in federal, state and local healthcare policies;

restrictive covenants in the Company's debt instruments;

present or future state regulations and contractual requirements that the Company provide financial assurance of its ability to meet its obligations;

the impact of the competitive environment in the managed healthcare services industry which may limit the Company's ability to maintain or obtain contracts, as well as its ability to maintain or increase its rates;

Table of Contents

the impact of healthcare reform legislation;

the Mental Health and Substance Abuse Benefit Parity Law and Regulations;

government regulation;

the unauthorized disclosure of sensitive or confidential member or other information;

the possible impact of additional regulatory scrutiny and liability associated with the Company's Pharmacy Solutions segment;

the inability to realize the value of goodwill and intangible assets;

pending or future actions or claims for professional liability;

claims brought against the Company that either exceed the scope of the Company's liability coverage or result in denial of coverage;

class action suits and other legal proceedings;

negative publicity;

the impact of governmental investigations;

the impact of varying economic and market conditions on the Company's investment portfolio; and

the state of the national economy and adverse changes in economic conditions.

Further discussion of factors currently known to management that could cause actual results to differ materially from those in forward-looking statements is set forth under the heading "Risk Factors" in Item 1A of Magellan's Annual Report on Form 10-K for the year ended December 31, 2012. When used in this Quarterly Report on Form 10-Q, the words "estimate," "anticipate," "expect," "believe," "should," and similar expressions are intended to be forward-looking statements. Magellan undertakes no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes to future operating results over time, except as required by law.

*Business Overview*

The Company is engaged in the specialty managed healthcare business. Through 2005, the Company predominantly operated in the managed behavioral healthcare business. As a result of certain acquisitions, the Company expanded into radiology benefits management and specialty pharmaceutical management during 2006, and into Medicaid administration during 2009. The Company provides services to health plans, insurance companies, employers, labor unions and various governmental agencies. The Company's business is divided into the following five segments, based on the services it provides and/or the customers that it serves, as described below.

Managed Behavioral Healthcare

Two of the Company's segments are in the managed behavioral healthcare business. This line of business generally reflects the Company's coordination and management of the delivery of behavioral healthcare treatment services that are provided through its contracted network of third-party treatment providers, which includes psychiatrists, psychologists, other behavioral health professionals, psychiatric hospitals, general medical facilities with psychiatric beds, residential treatment centers and other treatment facilities. The treatment services provided through the Company's provider network include outpatient programs (such as counseling or therapy), intermediate care programs (such as intensive outpatient programs and partial hospitalization services), inpatient treatment and crisis intervention

Table of Contents

services. The Company generally does not directly provide or own any provider of treatment services, although it does employ licensed behavioral health counselors to deliver non-medical counseling under certain government contracts.

The Company provides its management services primarily through: (i) risk-based products, where the Company assumes all or a substantial portion of the responsibility for the cost of providing treatment services in exchange for a fixed per member per month fee, (ii) ASO products, where the Company provides services such as utilization review, claims administration and/or provider network management, but does not assume responsibility for the cost of the treatment services, and (iii) EAPs where the Company provides short-term outpatient behavioral counseling services.

The managed behavioral healthcare business is managed based on the services provided and/or the customers served, through the following two segments:

*Commercial.* Commercial generally reflects managed behavioral healthcare services and EAP services provided under contracts with health plans and insurance companies for some or all of their commercial, Medicaid and Medicare members, as well as with employers, including corporations, governmental agencies, and labor unions. Commercial's contracts encompass risk-based, ASO and EAP arrangements. As of September 30, 2013, Commercial's covered lives were 4.8 million, 13.5 million and 12.6 million for risk-based, ASO and EAP products, respectively. For the nine months ended September 30, 2013, Commercial's revenue was \$382.3 million, \$89.2 million and \$106.5 million for risk-based, ASO and EAP products, respectively.

*Public Sector.* Public Sector generally reflects the management of behavioral health services provided to recipients under Medicaid and other state sponsored programs under contracts with state and local governmental agencies. Public Sector contracts also include management services for the integrated physical, behavioral and pharmaceutical care for special populations covered under Medicaid and other government sponsored programs. Public Sector contracts encompass either risk-based or ASO arrangements. As of September 30, 2013, Public Sector's covered lives were 2.1 million and 0.9 million for risk-based and ASO products, respectively. For the nine months ended September 30, 2013, Public Sector's revenue was \$1,242.4 million and \$24.3 million for risk-based and ASO products, respectively.

Radiology Benefits Management

Radiology Benefits Management generally reflects the management of the delivery of diagnostic imaging and other therapeutic services to ensure that such services are clinically appropriate and cost effective. The Company's radiology benefits management services currently are provided under contracts with health plans and insurance companies for some or all of their commercial, Medicaid and Medicare members. The Company also contracts with state and local governmental agencies for the provision of such services to Medicaid recipients. The Company offers its radiology benefits management services through risk-based contracts, where the Company assumes all or a substantial portion of the responsibility for the cost of providing diagnostic imaging services, and through ASO contracts, where the Company provides services such as utilization review and claims administration, but does not assume responsibility for the cost of the imaging services. As of September 30, 2013, covered lives for Radiology Benefits Management were 5.2 million and 12.3 million for risk-based and ASO products, respectively. For the nine months ended September 30, 2013, revenue for Radiology Benefits Management was \$247.3 million and \$29.8 million for risk-based and ASO products, respectively.

Table of Contents

Pharmacy Solutions

Pharmacy Solutions comprises products and solutions that provide clinical and financial management of drugs paid under medical and pharmacy benefit programs. The Company's Pharmacy Solutions services include (i) pharmacy benefit management programs; (ii) specialty contracting and formulary optimization programs; (iii) specialty pharmaceutical dispensing operations; (iv) medical pharmacy management programs; and (v) programs for the integrated management of drugs that treat complex conditions, regardless of site of service or benefit reimbursement. The Company's pharmacy solutions are provided under contracts with health plans, employers, Medicaid MCOs, state Medicaid programs, and other government agencies, and encompass risk-based and FFS arrangements. The Company's Pharmacy Solutions segment served 39 health plans and employers, 25 states and the District of Columbia, and several pharmaceutical manufacturers as of September 30, 2013.

Beginning in the first quarter of 2013, the Company underwent organizational changes. As a result of these changes, the Company concluded that changes to its reportable segments were warranted. This segment contains the operating segments previously defined as the Specialty Pharmaceutical Management segment and the Medicaid Administration segment. Prior period balances have been reclassified to reflect this change.

Corporate

This segment of the Company is comprised primarily of operational support functions such as sales and marketing and information technology, as well as corporate support functions such as executive, finance, human resources and legal.

*Significant Customers*

Consolidated Company

The Company provides behavioral healthcare management and other related services to approximately 685,000 members in Maricopa County, Arizona as the Regional Behavioral Health Authority ("RHBA") for GSA6 ("Maricopa County") pursuant to a contract with the State of Arizona (the "Maricopa Contract").

The Maricopa Contract is for the management of the publicly funded behavioral health system that delivers mental health, substance abuse and crisis services for adults, youth, and children. Under the Maricopa Contract, the Company is responsible for providing covered behavioral health services to persons eligible under Title XIX (Medicaid) and Title XXI (State Children's Health Insurance Program) of the Social Security Act, non-Title XIX and non-Title XXI eligible children and adults with a serious mental illness, and to certain non-Title XIX and non-Title XXI adults with behavioral health or substance abuse disorders. The Maricopa Contract began on September 1, 2007 and was scheduled to expire on October 1, 2013. The Company and the State of Arizona have agreed to extend the Maricopa Contract through March 31, 2014. The State of Arizona has the right to terminate the Maricopa Contract for cause, as defined, upon ten days' notice with an opportunity to cure, and, after January 1, 2014, without cause upon 30 days prior notice to the Company. The Maricopa Contract generated net revenues of \$566.2 million and \$557.6 million for the nine months ended September 30, 2012 and 2013, respectively.

The State of Arizona had previously issued a Solicitation for a new RBHA for Maricopa County (the "New Contract") to replace the current contract with the Company to be effective on October 1, 2013. The New Contract is for the management of the publicly funded behavioral health system currently provided by the Company under the Maricopa Contract, and also includes an integrated behavioral and physical health care system for a small number of individuals with serious mental illness.

## Edgar Filing: MAGELLAN HEALTH SERVICES INC - Form 10-Q

### Table of Contents

Magellan Complete Care of Arizona, a joint venture owned 80% by the Company and 20% by Vanguard/Phoenix Health Plan, previously submitted a bid for the Contract.

On March 25, 2013, the Company was notified that Magellan Complete Care of Arizona was not selected as the RBHA for the New Contract. On April 3, 2013, the Company filed a formal protest regarding the State's decision to award the RBHA in Maricopa County to another vendor. On April 17, 2013, the Arizona Department of Health Services denied the Company's protest. On May 9, 2013, the Company filed an appeal of the denial of its protest (the "Appeal") with the Arizona Department of Administration (the "DOA"), the agency responsible for considering appeals of procurement protest denials. The Company also filed with the DOA a motion to stay the award and implementation of the contract pending a decision on the Appeal. On May 21, 2013, the DOA granted the Company's motion and issued a stay of the award and implementation of the contract pending resolution of the Appeal by the DOA (the "Stay").

On June 13, 2013 the DOA referred the Appeal for a hearing before an independent administrative law judge in the Arizona Office of Administrative Hearings (the "OAH"). The OAH held an evidentiary hearing on the Appeal on September 18-27, 2013. Post-hearing briefing will be completed by October 29, 2013 and the Company anticipates the administrative law judge will issue her decision and recommendation to DOA on or before November 18, 2013. The DOA will then have 30 days to review the administrative law judge's decision and recommendation and issue its decision on Magellan's appeal of the protest denial. There is no assurance that the Company will prevail on the Appeal or that the Stay will remain in effect. In the event that the Company does not prevail on the Appeal, the Company will likely incur shutdown costs pertaining to the contract, including severance and lease termination charges. As of September 30, 2013, the Company has not accrued any such shutdown costs, which are estimated to be \$8 to \$12 million.

### By Segment

In addition to the Maricopa Contract previously discussed, the following customers generated in excess of ten percent of net revenues for the respective segment for the nine months ended September 30, 2012 and 2013 (in thousands):

Segment	Term Date	2012	2013
<b>Commercial</b>			
Customer A	Mid-2014(1)	\$ 144,499	\$ 156,269
Customer B	December 31, 2019	101,249	106,433
Customer C	December 31, 2012 to December 14, 2013(2)(3)	89,592	58,246
<b>Public Sector</b>			
Customer D	June 30, 2014(4)	175,440	209,266
<b>Radiology Benefits Management</b>			
Customer E	December 31, 2015	83,158	96,402
Customer F	June 30, 2014	44,959	43,490
Customer G	July 31, 2015	42,458	47,161
Customer H	January 31, 2014	27,824	34,338
<b>Pharmacy Solutions</b>			
Customer I	November 30, 2013 to December 31, 2013(2)	98,128	99,599
Customer J	December 31, 2013(5)	45,018	43,315*
Customer K	December 31, 2013(5)	53,640	68,166
Customer L	September 30, 2013(6)	53,259	48,527

\*

Revenue amount did not exceed ten percent of net revenues for the respective segment for the period presented. Amount is shown for comparative purposes only.



Table of Contents

- (1) The customer has informed the Company that, after a competitive evaluation process, it has decided not to renew its contract after the contract expires on December 31, 2013. The Company anticipates the contract will extend through mid-2014 to allow for transition to new vendor.
- (2) The customer has more than one contract. The individual contracts are scheduled to terminate at various points during the time period indicated above.
- (3) Revenues for the nine months ended September 30, 2012 of \$38.0 million relate to a contract that terminated as of December 31, 2012. The customer has informed the Company that is has decided not to renew the remaining contract after the contract expires on December 14, 2013.
- (4) Contract has options for the customer to extend the term for two additional one-year periods.
- (5) The Company has received notification that the customer will not renew its contracts for specialty pharmacy and related services. The Company has multiple contracts that are currently scheduled to terminate on December 31, 2013.
- (6) This customer represents a subcontract with a Public Sector customer and is eliminated in consolidation.

Concentration of Business

The Company also has a significant concentration of business with various counties in the State of Pennsylvania (the "Pennsylvania Counties") which are part of the Pennsylvania Medicaid program, and with various areas in the State of Florida (the "Florida Areas") which are part of the Florida Medicaid program. Net revenues from the Pennsylvania Counties in the aggregate totaled \$269.8 million and \$269.1 million for the nine months ended September 30, 2012 and 2013, respectively. Net revenues from the Florida Areas in the aggregate totaled \$100.6 million and \$97.8 million for the nine months ended September 30, 2012 and 2013, respectively.

The Company's contracts with customers typically have terms of one to three years, and in certain cases contain renewal provisions (at the customer's option) for successive terms of between one and two years (unless terminated earlier). Substantially all of these contracts may be immediately terminated with cause and many of the Company's contracts are terminable without cause by the customer or the Company either upon the giving of requisite notice and the passage of a specified period of time (typically between 60 and 180 days) or upon the occurrence of other specified events. In addition, the Company's contracts with federal, state and local governmental agencies generally are conditioned on legislative appropriations. These contracts generally can be terminated or modified by the customer if such appropriations are not made.

*Critical Accounting Policies and Estimates*

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Significant estimates of the Company include, among other things, accounts receivable realization, valuation allowances for deferred tax assets, valuation of goodwill and intangible assets, medical claims payable, other medical liabilities, stock compensation assumptions, tax contingencies and legal liabilities. Actual results could differ from those estimates. Except as noted below, the Company's critical accounting policies are summarized in the Company's Annual Report on Form 10-K, filed with the SEC on February 28, 2013.

Table of Contents

*Income Taxes*

The Company's effective income tax rates were 12.6 percent and 22.0 percent for the nine months ended September 30, 2012 and 2013, respectively. These rates differ from the federal statutory income tax rate primarily due to state income taxes, permanent differences between book and tax income, and changes to recorded tax contingencies. The Company also accrues interest and penalties related to unrecognized tax benefits in its provision for income taxes. The effective income tax rate for the nine months ended September 30, 2012 is lower than the effective rate for the nine months ended September 30, 2013 mainly due to lower reversals of tax contingencies in the current year from the closure of statutes of limitation.

The Company files a consolidated federal income tax return for the Company and its eighty percent or more owned subsidiaries, and the Company and its subsidiaries file income tax returns in various states and local jurisdictions. With few exceptions, the Company is no longer subject to state or local income tax assessments by tax authorities for years ended prior to 2009. Further, the statutes of limitation regarding the assessment of federal and certain state and local income taxes for 2009 closed during the current quarter. As a result, \$27.2 million of unrecognized tax benefits (excluding interest costs) recorded as of December 31, 2012 were reversed in the current quarter, of which \$22.7 million is reflected as a discrete reduction to income tax expense, \$3.9 million as an increase to additional paid-in capital, and the remainder as a decrease to deferred tax assets. Additionally, \$2.1 million of accrued interest was reversed in the current quarter and reflected as a reduction to income tax expense due to the closing of statutes of limitation on tax assessments.

*Results of Operations*

The accounting policies of the Company's segments are the same as those described in Note A "General." The Company evaluates performance of its segments based on Segment Profit. Management uses Segment Profit information for internal reporting and control purposes and considers it important in making decisions regarding the allocation of capital and other resources, risk assessment and employee compensation, among other matters. Effective September 1, 2010, Public Sector has subcontracted with Pharmacy Solutions to provide pharmacy benefits management services on a risk basis for one of Public Sector's customers. As such, revenue and cost of care related to this intersegment arrangement are eliminated. The Company's segments are defined above. The Pharmacy Solutions segment contains the operating segments previously defined as the Specialty Pharmaceutical Management segment and the Medicaid Administration segment. Prior period balances have been reclassified to reflect this change.

Edgar Filing: MAGELLAN HEALTH SERVICES INC - Form 10-Q

Table of Contents

The following tables summarize, for the periods indicated, operating results by business segment (in thousands):

	Commercial	Public Sector	Radiology Benefits Management	Pharmacy Solutions	Corporate and Elimination	Consolidated
<b>Three Months Ended September 30, 2012</b>						
Managed care and other revenue	\$ 176,713	\$ 407,265	\$ 88,126	\$ 54,421	\$ (15,433)	\$ 711,092
Dispensing revenue				87,345		87,345
Cost of care	(100,973)	(358,959)	(58,080)	(13,659)	15,433	(516,238)
Cost of goods sold				(81,662)		(81,662)
Direct service costs and other	(43,007)	(22,948)	(14,045)	(27,565)	(28,009)	(135,574)
Stock compensation expense(1)	293	278	419	238	3,240	4,468
Segment profit (loss)	\$ 33,026	\$ 25,636	\$ 16,420	\$ 19,118	\$ (24,769)	\$ 69,431

	Commercial	Public Sector	Radiology Benefits Management	Pharmacy Solutions	Corporate and Elimination	Consolidated
<b>Three Months Ended September 30, 2013</b>						
Managed care and other revenue	\$ 190,655	\$ 445,260	\$ 94,125	\$ 63,008	\$ (17,091)	\$ 775,957
Dispensing revenue				97,641		97,641
Cost of care	(118,022)	(382,913)	(65,403)	(20,940)	17,091	(570,187)
Cost of goods sold				(91,853)		(91,853)
Direct service costs and other	(47,032)	(27,826)	(13,990)	(32,281)	(35,705)	(156,834)
Stock compensation expense(1)	124	259	384	198	3,559	4,524
Segment profit (loss)	\$ 25,725	\$ 34,780	\$ 15,116	\$ 15,773	\$ (32,146)	\$ 59,248

	Commercial	Public Sector	Radiology Benefits Management	Pharmacy Solutions	Corporate and Elimination	Consolidated
<b>Nine Months Ended September 30, 2012</b>						
Managed care and other revenue	\$ 535,464	\$ 1,206,289	\$ 253,809	\$ 171,846	\$ (53,259)	\$ 2,114,149
Dispensing revenue				262,974		262,974
Cost of care	(323,992)	(1,058,384)	(166,364)	(47,880)	53,259	(1,543,361)
Cost of goods sold				(245,555)		(245,555)
Direct service costs and other	(127,825)	(66,850)	(41,113)	(83,532)	(93,176)	(412,496)
Stock compensation expense(1)	830	835	1,179	704	10,387	13,935
Segment profit (loss)	\$ 84,477	\$ 81,890	\$ 47,511	\$ 58,557	\$ (82,789)	\$ 189,646

Table of Contents

	Commercial	Public Sector	Radiology Benefits Management	Pharmacy Solutions	Corporate and Elimination	Consolidated
<b>Nine Months Ended September 30, 2013</b>						
Managed care and other revenue	\$ 578,030	\$ 1,266,739	\$ 277,118	\$ 182,418	\$ (48,557)	\$ 2,255,748
Dispensing revenue				282,359		282,359
Cost of care	(354,520)	(1,095,694)	(182,212)	(59,075)	48,557	(1,642,944)
Cost of goods sold				(265,440)		(265,440)
Direct service costs and other	(129,823)	(82,403)	(41,224)	(93,216)	(94,292)	(440,958)
Stock compensation expense(1)	390	833	1,275	898	11,368	14,764
Segment profit (loss)	\$ 94,077	\$ 89,475	\$ 54,957	\$ 47,944	\$ (82,924)	\$ 203,529

(1)

Stock compensation expense is included in direct service costs and other operating expenses, however this amount is excluded from the computation of Segment Profit since it is managed on a consolidated basis.

The following table reconciles Segment Profit to income before income taxes (in thousands):

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2012	2013	2012	2013
Segment profit	\$ 69,431	\$ 59,248	\$ 189,646	\$ 203,529
Stock compensation expense	(4,468)	(4,524)	(13,935)	(14,764)
Depreciation and amortization	(15,239)	(17,654)	(45,172)	(50,770)
Interest expense	(537)	(789)	(1,713)	(2,191)
Interest income	350	291	1,619	1,002
Income before income taxes	\$ 49,537	\$ 36,572	\$ 130,445	\$ 136,806

**Quarter ended September 30, 2013 ("Current Year Quarter"), compared to the quarter ended September 30, 2012 ("Prior Year Quarter")**

**Commercial***Net Revenue*

Net revenue related to Commercial increased by 7.9 percent or \$13.9 million from the Prior Year Quarter to the Current Year Quarter. The increase in revenue is mainly due to new contracts implemented after (or during) the Prior Year Quarter of \$19.1 million, increased membership from existing customers of \$7.4 million, favorable rate changes of \$5.3 million, retroactive risk share adjustments recorded in the Prior Year Quarter of \$1.6 million and other net favorable increases of \$1.0 million. These increases were partially offset by terminated contracts of \$19.1 million and retroactive rate and membership adjustments of \$1.4 million recorded in the Prior Year Quarter.

*Cost of Care*

Cost of care increased by 16.9 percent or \$17.0 million from the Prior Year Quarter to the Current Year Quarter. The increase in cost of care is primarily due to new contracts of \$12.1 million, favorable prior period medical claims development recorded in the Prior Year Quarter of \$4.9 million,



Table of Contents

membership from existing customers of \$4.8 million and unfavorable care trends and other net variances of \$12.4 million. These increases were partially offset by terminated contracts of \$14.9 million and favorable medical claims development for the Prior Year Quarter which was recorded after the Prior Year Quarter of \$2.3 million. Cost of care increased as a percentage of risk revenue (excluding EAP business) from 73.9 percent in the Prior Year Quarter to 80.2 percent in the Current Year Quarter, mainly due to unfavorable care trends in excess of favorable rate changes.

*Direct Service Costs*

Direct service costs increased by 9.4 percent or \$4.0 million from the Prior Year Quarter to the Current Year Quarter primarily due to severance and restructuring costs pertaining to terminated contracts of \$5.0 million, which increase was partially offset by other net favorable variances of \$1.0 million. Direct service costs increased as a percentage of revenue from 24.3 percent in the Prior Year Quarter to 24.7 percent in the Current Year Quarter, mainly due to the severance and restructuring charges incurred in the Current Year Quarter.

**Public Sector**

*Net Revenue*

Net revenue related to Public Sector increased by 9.3 percent or \$38.0 million from the Prior Year Quarter to the Current Year Quarter. This increase is primarily due to new contracts implemented after the Prior Year Quarter of \$29.5 million, increased membership from existing customers of \$5.1 million, additional revenue for provider incentives of \$1.8 million, the revenue impact of favorable prior period care development recorded in the Current Year Quarter of \$1.3 million and other net favorable variances of \$3.7 million. These increases were partially offset by unfavorable rate changes of \$3.4 million.

*Cost of Care*

Cost of care increased by 6.7 percent or \$24.0 million from the Prior Year Quarter to the Current Year Quarter. This increase is primarily due to new contracts of \$27.3 million, increased membership from existing customers of \$3.7 million and unfavorable care trends and other net variances of \$6.4 million. These increases were partially offset by favorable prior period care development recorded in the Current Year Quarter of \$10.7 million and care associated with rate changes for contracts with minimum care requirements of \$2.7 million. Cost of care decreased as a percentage of risk revenue from 89.9 percent in the Prior Year Quarter to 87.6 percent in the Current Year Quarter mainly due to favorable prior period care development.

*Direct Service Costs*

Direct service costs increased by 21.3 percent or \$4.9 million from the Prior Year Quarter to the Current Year Quarter, mainly due to costs to support new business and development costs for the Magellan Complete Care product. Direct service costs increased as a percentage of revenue from 5.6 percent for the Prior Year Quarter to 6.3 percent in the Current Year Quarter mainly due to development costs for the Magellan Complete Care product.

**Radiology Benefits Management**

*Net Revenue*

Net revenue related to Radiology Benefits Management increased by 6.8 percent or \$6.0 million from the Prior Year Quarter to the Current Year Quarter. This increase is primarily due to new contracts implemented after (or during) the Prior Year Quarter of \$11.3 million, increase in

Table of Contents

membership from existing customers of \$2.0 million and other net favorable variances of \$3.6 million. These increases were partially offset by unfavorable rate changes of \$6.4 million, terminated contracts of \$3.8 million and retroactive rate and membership adjustments recorded in the Prior Year Quarter of \$0.7 million.

*Cost of Care*

Cost of care increased by 12.6 percent or \$7.3 million from the Prior Year Quarter to the Current Year Quarter. This increase is primarily attributed to new contracts of \$8.9 million, increased membership from existing customers of \$1.0 million and care trends and other net unfavorable variances of \$2.6 million. These increases were partially offset by terminated contracts of \$3.1 million and favorable medical claims development for the Prior Year Quarter recorded after the Prior Year Quarter of \$2.1 million. Cost of care increased as a percentage of risk revenue from 74.0 percent in the Prior Year Quarter to 77.8 percent in the Current Year Quarter mainly due to unfavorable rate changes and care trends.

*Direct Service Costs*

Direct service costs decreased by 0.4 percent or \$0.1 million from the Prior Year Quarter to the Current Year Quarter. As a percentage of revenue, direct service costs decreased from 15.9 percent in the Prior Year Quarter to 14.9 percent in the Current Year Quarter, as the Company was able to add net new business without increasing direct service costs.

**Pharmacy Solutions**

*Net Revenue*

Net revenue related to Pharmacy Solutions increased by 13.3 percent or \$18.9 million from the Prior Year Quarter to the Current Year Quarter. This increase is primarily due to net increased dispensing activity from existing customers of \$9.8 million, new business of \$7.1 million (mainly PBM), increased revenue from a subcontract with Public Sector of \$1.6 million and other net increases of \$1.0 million. These increases were partially offset by retroactive revenue adjustments recorded in the Prior Year Quarter of \$0.6 million.

*Cost of Care*

Cost of care increased by 53.3 percent or \$7.3 million from the Prior Year Quarter to the Current Year Quarter. This increase is primarily due to new PBM business of \$5.7 million and unfavorable care trends of \$1.6 million. Cost of care increased as a percentage of risk revenue from 88.5 percent in the Prior Year Quarter to 91.4 percent in the Current Year Quarter, mainly due to business mix.

*Cost of Goods Sold*

Cost of goods sold increased by 12.5 percent or \$10.2 million from the Prior Year Quarter to the Current Year Quarter. This increase is primarily due to increased dispensing activity from existing customers. As a percentage of the portion of net revenue that relates to dispensing activity, cost of goods sold increased from 93.4 percent in the Prior Year Quarter to 94.1 percent in the Current Year Quarter, mainly due to business mix.

*Direct Service Costs*

Direct service costs increased by 17.1 percent or \$4.7 million from the Prior Year Quarter to the Current Year Quarter. This increase mainly relates to implementation costs and ongoing costs to support new business. As a percentage of revenue, direct service costs increased from 19.4 percent in

Table of Contents

the Prior Year Quarter to 20.1 percent in the Current Year Quarter, mainly due to implementation costs and ongoing costs to support new business.

***Corporate and Other***

*Other Operating Expenses*

Other operating expenses related to the Corporate and Other segment increased by 27.5 percent or \$7.7 million from the Prior Year Quarter to the Current Year Quarter. The increase relates primarily from discretionary benefits of \$4.3 million and severance and other one time items in the Current Year Quarter of \$3.4 million. As a percentage of total net revenue, other operating expenses increased from 3.5 percent for the Prior Year Quarter to 4.1 percent for the Current Year Quarter, primarily due to severance and other one time items.

*Depreciation and Amortization*

Depreciation and amortization expense increased by 15.9 percent or \$2.4 million from the Prior Year Quarter to the Current Year Quarter, primarily due to asset additions after the Prior Year Quarter.

*Interest Expense*

Interest expense increased by 46.9 percent or \$0.3 million from the Prior Year Quarter to the Current Year Quarter, mainly due to capital lease additions after the Prior Year Quarter.

*Interest Income*

Interest income decreased by 16.9 percent or \$0.1 million from the Prior Year Quarter to the Current Year Quarter, mainly due to lower yields on investments in Current Year Quarter.

*Income Taxes*

The Company's effective income tax rates were (33.8) percent and (29.2) percent for the Prior Year Quarter and Current Year Quarter, respectively. The effective income tax rate for the Current Year Quarter differs from the Prior Year Quarter effective rate mainly due to lower reversals of tax contingencies in the Current Year Quarter from the closure of statutes of limitation.

The statutes of limitation regarding the assessment of federal and certain state and local income taxes for 2009 closed during the Current Year Quarter. As a result, \$27.2 million of unrecognized tax benefits recorded as of December 31, 2012 were reversed in the Current Year Quarter, of which \$22.7 million is reflected as a discrete reduction to income tax expense, \$3.9 million as an increase to additional paid-in capital, and the remainder as a decrease to deferred tax assets. Additionally, \$2.1 million of accrued interest was reversed in the Current Year Quarter and reflected as a reduction to income tax expense due to the closing of statutes of limitation on tax assessments.

The statutes of limitation regarding the assessment of federal and certain state and local income taxes for 2008 closed during the Prior Year Quarter. As a result, \$41.6 million of unrecognized tax benefits recorded as of December 31, 2011 were reversed in the Prior Year Quarter, of which \$34.7 million was reflected as a discrete reduction to income tax expense, \$6.2 million as an increase to additional paid-in capital, and the remainder as a decrease to deferred tax assets. Additionally, \$1.1 million of accrued interest and \$1.0 million of unrecognized state tax benefits were reversed in the Prior Year Quarter and reflected as reductions to income tax expense due to the closing of statutes of limitation on tax assessments and changes in tax return elections, respectively.



Table of Contents

**Nine months ended September 30, 2013 ("Current Year Period"), compared to the nine months ended September 30, 2012 ("Prior Year Period")**

***Commercial***

*Net Revenue*

Net revenue related to Commercial increased by 7.9 percent or \$42.6 million from the Prior Year Period to the Current Year Period. The increase in revenue is mainly due to new contracts implemented after (or during) the Prior Year Period of \$50.0 million, favorable rate changes of \$28.1 million, increased membership from existing customers of \$14.0 million, customers settlements in the Current Year Period of \$6.7 million, retroactive rate and membership adjustments recorded in the Current Year Period of \$1.4 million and retroactive risk share adjustments recorded in the Prior Year Period of \$1.2 million. These increases were partially offset by terminated contracts of \$45.8 million, performance-based revenue recorded in the Prior Year Period of \$10.5 million and other net decreases of \$2.5 million.

*Cost of Care*

Cost of care increased by 9.4 percent or \$30.5 million from the Prior Year Period to the Current Year Period. The increase in cost of care is primarily due to new contracts of \$32.9 million, increased membership from existing customers of \$8.5 million, favorable prior period medical claims development recorded in the Prior Year Period of \$3.2 million and unfavorable care trends and other net variances of \$28.1 million. These increases were partially offset by terminated contracts of \$36.1 million, favorable prior period medical claims development recorded in the Current Year Period of \$4.5 million and favorable medical claims development for the Prior Year Period which was recorded after the Prior Year Period of \$1.6 million. Cost of care increased as a percentage of risk revenue (excluding EAP business) from 79.1 percent in the Prior Year Period to 79.4 percent in the Current Year Period, mainly due to business mix.

*Direct Service Costs*

Direct service costs increased by 1.6 percent or \$2.0 million from the Prior Year Period to the Current Year Period primarily due to severance and restructuring costs pertaining to terminated contracts of \$5.0 million, partially offset by reduced costs as a result of cost containment efforts. Direct service costs decreased as a percentage of revenue from 23.9 percent in the Prior Year Period to 22.5 percent in the Current Year Period, mainly due to cost containment efforts and the impact of increased revenue from favorable rate changes.

***Public Sector***

*Net Revenue*

Net revenue related to Public Sector increased by 5.0 percent or \$60.5 million from the Prior Year Period to the Current Year Period. This increase is primarily due to new contracts implemented after (or during) the Prior Year Period of \$71.2 million, performance incentive revenue in the Current Year Period of \$2.7 million and other net favorable variances of \$3.1 million. These increases were partially offset by unfavorable rate changes of \$11.8 million and decreased membership from existing customers of \$4.7 million.

*Cost of Care*

Cost of care increased by 3.5 percent or \$37.3 million from the Prior Year Period to the Current Year Period. This increase is primarily due to new contracts of \$60.3 million, favorable contractual settlements of \$2.2 million in the Prior Year Period and unfavorable care trends and other net

Table of Contents

unfavorable variances of \$16.3 million. These increases were partially offset by favorable prior period medical claims development recorded in the Current Year Period of \$18.0 million, care associated with rate changes for contracts with minimum care requirements of \$9.7 million, favorable medical claims development for prior year period recorded after the prior year period of \$7.6 million and decreased membership from existing customers of \$6.2 million. Cost of care decreased as a percentage of risk revenue from 89.2 percent in the Prior Year Period to 88.2 percent in the Current Year Period mainly due to favorable medical claims development.

*Direct Service Costs*

Direct service costs increased by 23.3 percent or \$15.6 million from the Prior Year Period to the Current Year Period, mainly due to costs to support new business and development costs for the Magellan Complete Care product. Direct service costs increased as a percentage of revenue from 5.5 percent for the Prior Year Period to 6.5 percent in the Current Year Period mainly due to development costs for the Magellan Complete Care product.

***Radiology Benefits Management***

*Net Revenue*

Net revenue related to Radiology Benefits Management increased by 9.2 percent or \$23.3 million from the Prior Year Period to the Current Year Period. This increase is primarily due to new contracts implemented after (or during) the Prior Year Period of \$33.2 million, increased membership from existing customers of \$9.0 million and other net favorable variances of \$1.4 million. These increases were partially offset by unfavorable rate changes of \$7.1 million, terminated contracts of \$6.8 million, favorable contractual settlements of \$4.4 million in the Prior Year Period and the revenue impact of favorable prior period care development recorded in the Current Year Period of \$2.0 million.

*Cost of Care*

Cost of care increased by 9.5 percent or \$15.8 million from the Prior Year Period to the Current Year Period. This increase is primarily attributed to new contracts of \$26.8 million and increased membership from existing customers of \$5.3 million. These increases were partially offset by favorable prior period medical claims development recorded in the Current Year Period of \$5.5 million, terminated contracts of \$5.1 million, favorable medical claims development for the Prior Year Period recorded after the Prior Year Period of \$4.7 million and care trends and other net favorable variances of \$1.0 million. Cost of care decreased as a percentage of risk revenue from 74.5 percent in the Prior Year Period to 73.7 percent in the Current Year Period mainly due to favorable medical claims development and care trends.

*Direct Service Costs*

Direct service costs increased by 0.3 percent or \$0.1 million from the Prior Year Period to the Current Year Period. As a percentage of revenue, direct service costs decreased from 16.2 percent in the Prior Year Period to 14.9 percent in the Current Year Period, mainly due to changes in business mix.

***Pharmacy Solutions***

*Net Revenue*

Net revenue related to Pharmacy Solutions increased by 6.9 percent or \$30.0 million from the Prior Year Period to the Current Year Period. This increase is primarily due to net increased dispensing activity from existing customers of \$23.1 million, new business of \$17.5 million (mainly PBM) and

Table of Contents

increased other net favorable variances of \$2.7 million. These increases were partially offset by terminated contracts of \$5.6 million, a reduction to revenue associated with profit share recorded due to favorable cost of care trends of \$4.7 million, decreased formulary optimization revenue of \$2.1 million and retroactive revenue adjustments recorded in the Prior Year Period of \$0.9 million.

*Cost of Care*

Cost of care increased by 23.4 percent or \$11.2 million from the Prior Year Period to the Current Year Period. This increase is primarily due to new PBM business of \$15.8 million, partially offset by favorable care trends of \$4.6 million. Cost of care increased as a percentage of risk revenue from 89.9 percent in the Prior Year Period to 91.1 percent in the Current Year Period, mainly due to business mix.

*Cost of Goods Sold*

Cost of goods sold increased by 8.1 percent or \$19.9 million from the Prior Year Period to the Current Year Period. This increase is primarily due to increased dispensing activity of \$23.7 million, partially offset by terminated contracts of \$3.8 million. As a percentage of the portion of net revenue that relates to dispensing activity, cost of goods sold increased from 93.4 percent in the Prior Year Period to 94.0 percent in the Current Year Period, mainly due to business mix.

*Direct Service Costs*

Direct service costs increased by 11.6 percent or \$9.7 million from the Prior Year Period to the Current Year Period. This increase mainly relates to implementation costs and ongoing costs to support new business. As a percentage of revenue, direct service costs increased from 19.2 percent in the Prior Year Period to 20.1 percent in the Current Year Period, mainly due to implementation costs and ongoing costs to support new business.

*Corporate and Other*

*Other Operating Expenses*

Other operating expenses related to the Corporate and Other segment increased by 1.2 percent or \$1.1 million from the Prior Year Period to the Current Year Period. The increase results primary from severance and other one time items in the Current Year Period of \$3.8 million and an increase in stock compensation expense of \$1.0 million, which increases were partially offset by expenses incurred to support growth initiatives in the Prior Year Period. As a percentage of total net revenue, other operating expenses decreased from 3.9 percent for the Prior Year Period to 3.7 percent for the Current Year Period, primarily due to increased revenue from new business, as well as the inclusion in the Prior Year Period of expenses incurred to support growth initiatives.

*Depreciation and Amortization*

Depreciation and amortization expense increased by 12.4 percent or \$5.6 million from the Prior Year Period to the Current Year Period, primarily due to asset additions after the Prior Year Period.

*Interest Expense*

Interest expense increased by 27.9 percent or \$0.5 million from the Prior Year Period to the Current Year Period, primarily due to capital leases additions after the Prior Year Period.

Table of Contents

*Interest Income*

Interest income decreased by 38.1 percent or \$0.6 million from the Prior Year Period to the Current Year Period, primarily due to lower yields on investments in the Current Year Period.

*Income Taxes*

The Company's effective income tax rates were 12.6 percent and 22.0 percent for the Prior Year Period and Current Year Period, respectively. The effective income tax rate for the Prior Year Period is lower than the Current Year Period effective rate mainly due to lower reversals of tax contingencies in the Current Year Period from the closure of statutes of limitation.

The statutes of limitation regarding the assessment of federal and certain state and local income taxes for 2009 closed during the Current Year Period. As a result, \$27.2 million of unrecognized tax benefits recorded as of December 31, 2012 were reversed in the Current Year Period, of which \$22.7 million is reflected as a discrete reduction to income tax expense, \$3.9 million as an increase to additional paid-in capital, and the remainder as a decrease to deferred tax assets. Additionally, \$2.1 million of accrued interest was reversed in the Current Year Period and reflected as a reduction to income tax expense due to the closing of statutes of limitation on tax assessments.

The statutes of limitation regarding the assessment of federal and certain state and local income taxes for 2008 closed during the Prior Year Period. As a result, \$41.6 million of unrecognized tax benefits recorded as of December 31, 2011 were reversed in the Prior Year Period, of which \$34.7 million was reflected as a discrete reduction to income tax expense, \$6.2 million as an increase to additional paid-in capital, and the remainder as a decrease to deferred tax assets. Additionally, \$1.1 million of accrued interest and \$1.0 million of unrecognized state tax benefits were reversed in the Prior Year Period and reflected as reductions to income tax expense due to the closing of statutes of limitation on tax assessments and changes in tax return elections, respectively.

***Outlook Results of Operations***

The Company's Segment Profit and net income are subject to significant fluctuations from period to period. These fluctuations may result from a variety of factors such as those set forth under Item 2 "Forward-Looking Statements" as well as a variety of other factors including: (i) changes in utilization levels by enrolled members of the Company's risk-based contracts, including seasonal utilization patterns; (ii) contractual adjustments and settlements; (iii) retrospective membership adjustments; (iv) timing of implementation of new contracts, enrollment changes and contract terminations; (v) pricing adjustments upon contract renewals (and price competition in general); and (vi) changes in estimates regarding medical costs and IBNR.

A portion of the Company's business is subject to rising care costs due to an increase in the number and frequency of covered members seeking behavioral healthcare or radiology services, higher costs per inpatient day or outpatient visit for behavioral services, and higher costs per scan for radiology services. Many of these factors are beyond the Company's control. Future results of operations will be heavily dependent on management's ability to obtain customer rate increases that are consistent with care cost increases and/or to reduce operating expenses.

In relation to the managed behavioral healthcare business, the Company is a market leader in a mature market with many viable competitors. The Company is continuing its attempts to grow its business in the managed behavioral healthcare industry through aggressive marketing and development of new products; however, due to the maturity of the market, the Company believes that the ability to grow its current business lines may be limited. In addition, as previously discussed, substantially all of the Company's Commercial segment revenues are derived from Blue Cross Blue Shield health plans and other managed care companies, health insurers and health plans. In the past, certain of the

Table of Contents

managed care customers of the Company have decided not to renew all or part of their contracts with the Company, and to instead manage the behavioral healthcare services directly for their subscribers.

*Care Trends.* The Company expects that same-store normalized cost of care trend for the 12-month forward outlook to be 6 to 8 percent for Commercial, 0 to 2 percent for Public Sector and 3 to 5 percent for Radiology Benefits Management.

*Interest Rate Risk.* Changes in interest rates affect interest income earned on the Company's cash equivalents and investments, as well as interest expense on variable interest rate borrowings under the Company's 2011 Credit Facility. Based on the amount of cash equivalents and investments and the borrowing levels under the 2011 Credit Facility as of September 30, 2013, a hypothetical 10 percent increase or decrease in the interest rate associated with these instruments, with all other variables held constant, would not materially affect the Company's future earnings and cash outflows.

***Historical Liquidity and Capital Resources***

*Operating Activities.* The Company reported net cash provided by operating activities of \$111.7 million and \$171.3 million for the Prior Year Period and Current Year Period, respectively. The \$59.6 million increase in operating cash flows from the Prior Year Period to the Current Year Period is primarily attributable to the increase in Segment Profit between periods and the impact of the net shift of restricted funds between cash and investments that results in an operating cash flow change that is directly offset by an investing cash flow change. Partially offsetting these items is an increase in tax payments and the net unfavorable impact of working capital changes between periods.

Segment Profit for the Current Year Period increased \$13.9 million from the Prior Year Period. During the Prior Year Period, restricted investments of \$27.4 million were shifted to restricted cash that reduced operating cash flows, with restricted cash of \$33.6 million shifted to restricted investments during the Current Year Period that increased operating cash flows. The net impact of the shift in restricted funds between periods is an increase in operating cash flows of \$61.0 million. Tax payments for the Current Year Period totaled \$55.0 million, which represents an increase of \$15.1 million from the Prior Year Period. The net unfavorable impact of working capital changes for the Prior Year Period and Current Year Period totaled \$10.6 million and \$10.8 million, respectively.

During the Current Year Period, the Company's restricted cash decreased \$18.0 million. The change in restricted cash is attributable to the net shift of restricted cash to restricted investments of \$33.6 million, partially offset by an increase in restricted cash of \$14.7 million associated with the Company's regulated entities and other net increases of \$0.9 million. The net change in restricted cash for the Company's regulated entities is attributable to a net increase of \$15.8 million in restricted cash requirements that resulted in an operating cash flow use, partially offset by a net decrease in restricted cash of \$1.1 million that is offset by changes in other assets and liabilities, primarily accounts receivable, accrued liabilities, medical claims payable and other medical liabilities, thus having no impact on operating cash flows.

*Investing Activities.* The Company utilized \$53.0 million and \$42.1 million during the Prior Year Period and Current Year Period, respectively, for capital expenditures. The additions related to hard assets (equipment, furniture, leaseholds) and capitalized software for the Prior Year Period were \$26.3 million and \$26.7 million, respectively, as compared to additions for the Current Year Period related to hard assets and capitalized software of \$12.1 million and \$30.0 million, respectively. During the Prior Year Period the Company received net cash of \$17.6 million for the net maturity of "available for sale" securities, with the Company using net cash of \$2.2 million during the Current Year Period for the net purchase of "available-for-sale" securities. In addition, during the Current Year Period the Company executed a note receivable in the amount of \$5.9 million and purchased preferred stock of

Table of Contents

\$2.0 million from a third party. These transactions were made to support the growth initiatives involving Medicaid and other special populations.

*Financing Activities.* During the Prior Year Period, the Company received \$13.1 million from the exercise of stock options and had other net unfavorable items of \$0.1 million.

During the Current Year Period, the Company paid \$49.5 million for the repurchase of treasury stock under the Company's share repurchase program and paid \$2.3 million on capital lease obligations. In addition, the Company received \$24.6 million from the exercise of stock options and had other net favorable items of \$0.5 million

***Outlook Liquidity and Capital Resources***

*Liquidity.* During the remainder of 2013, the Company expects to fund its estimated capital expenditures of \$10 million to \$20 million with cash from operations. The Company does not anticipate that it will need to draw on amounts available under the 2011 Credit Facility for cash flow needs related to its operations, capital needs or debt service in 2013. The Company also currently expects to have adequate liquidity to satisfy its existing financial commitments over the periods in which they will become due. The Company plans to maintain its current investment strategy of investing in a diversified, high quality, liquid portfolio of investments and continues to closely monitor the situation in the financial markets. The Company estimates that it has no risk of any material permanent loss on its investment portfolio; however, there can be no assurance that the Company will not experience any such losses in the future.

*Stock Repurchases.* On October 25, 2011 the Company's board of directors approved a stock repurchase plan which authorized the Company to purchase up to \$200 million of its outstanding common stock through October 25, 2013. On July 24, 2013 the Company's board of directors approved an increase and extension of the stock repurchase plan which authorizes the Company to purchase up to \$300 million of its outstanding stock through October 25, 2015.

Stock repurchases under the program may be purchased from time to time in open market transactions (including blocks) or in privately negotiated transactions. The timing of repurchases and the actual amount purchased will depend on a variety of factors including the market price of the Company's shares, general market and economic conditions, and other corporate considerations. Repurchases may be made pursuant to plans intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, which could allow the Company to purchase its shares during periods when it otherwise might be prevented from doing so under insider trading laws or because of self-imposed trading blackout periods. Repurchases are expected to be funded from working capital and anticipated cash from operations. The repurchase authorization does not require the purchase of a specific number of shares and is subject to suspension or termination by the Company's board of directors at any time. Pursuant to this program, the Company made open market purchases of 671,776 shares of the Company's common stock at an average price of \$48.72 per share for an aggregate cost of \$32.7 million (excluding broker commissions) during the period from November 11, 2011 through December 31, 2011. Pursuant to this program, the Company made open market purchases of 459,252 shares of the Company's common stock at an average price of \$50.27 per share for an aggregate cost of \$23.1 million (excluding broker commissions) during 2012. Pursuant to this program, the Company made open market purchases of 955,776 shares of the Company's common stock at an average price of \$50.23 per share for an aggregate cost of \$48.0 million (excluding broker commissions) during the nine months ended September 30, 2013. As of September 30, 2013, the total dollar value remaining under the current authorization was \$196.2 million.

The Company made no open market purchases for the period from October 1, 2013 through October 21, 2013.

## Edgar Filing: MAGELLAN HEALTH SERVICES INC - Form 10-Q

### Table of Contents

*Off-Balance Sheet Arrangements.* As of September 30, 2013, the Company has no material off-balance sheet arrangements.

*2011 Credit Facility.* On December 9, 2011, the Company entered into a Senior Secured Revolving Credit Facility Credit Agreement with Citibank, N.A., Wells Fargo Bank, N.A., Bank of America, N.A., and U.S. Bank, N.A. that provides for up to \$230.0 million of revolving loans with a sublimit of up to \$70.0 million for the issuance of letters of credit for the account of the Company (the "2011 Credit Facility"). Citibank, N.A., has assigned a portion of its interest in the 2011 Credit Facility to Bank of Tokyo. The 2011 Credit Facility is guaranteed by substantially all of the subsidiaries of the Company and is secured by substantially all of the assets of the Company and the subsidiary guarantors. The 2011 Credit Facility will mature on December 9, 2014.

Under the 2011 Credit Facility, the annual interest rate on revolving loan borrowings is equal to (i) in the case of U.S. dollar denominated loans, the sum of a borrowing margin of 0.75 percent plus the higher of the prime rate, one-half of one percent in excess of the overnight "federal funds" rate, or the Eurodollar rate for one month plus 1.00 percent, or (ii) in the case of Eurodollar denominated loans, the sum of a borrowing margin of 1.75 percent plus the Eurodollar rate for the selected interest period. The Company has the option to borrow in U.S. dollar denominated loans or Eurodollar denominated loans at its discretion. Letters of credit issued under the Revolving Loan Commitment bear interest at the rate of 1.875 percent. The commitment commission on the 2011 Credit Facility is 0.375 percent of the unused Revolving Loan Commitment.

*Restrictive Covenants in Debt Agreements.* The 2011 Credit Facility contains covenants that limit management's discretion in operating the Company's business by restricting or limiting the Company's ability, among other things, to:

incur or guarantee additional indebtedness or issue preferred or redeemable stock;

pay dividends and make other distributions;

repurchase equity interests;

make certain advances, investments and loans;

enter into sale and leaseback transactions;

create liens;

sell and otherwise dispose of assets;

acquire or merge or consolidate with another company; and

enter into some types of transactions with affiliates.

These restrictions could adversely affect the Company's ability to finance future operations or capital needs or engage in other business activities that may be in the Company's interest.

The 2011 Credit Facility also requires the Company to comply with specified financial ratios and tests. Failure to do so, unless waived by the lenders under the 2011 Credit Facility pursuant to its terms, would result in an event of default under the 2011 Credit Facility. As of September 30, 2013, the Company was in compliance with all covenants, including financial covenants, under the 2011 Credit Facility.

Although the 2011 Credit Facility expires on December 9, 2014, the Company believes it will be able to obtain a new facility or, if not, to use cash on hand to fund letters of credit and other liquidity needs.





Table of Contents

*Net Operating Loss Carryforwards.* The Company had federal net operating loss carryforwards ("NOLs") as of December 31, 2012 of approximately \$4.2 million available to reduce future federal taxable income. These NOLs, if not used, expire in 2017 through 2019 and are subject to examination and adjustment by the IRS. Utilization of these NOLs is also subject to certain timing limitations, although the Company does not believe these limitations will restrict its ability to use any federal NOLs before they expire.

Deferred tax assets as of September 30, 2012 and 2013 are shown net of valuation allowances of \$3.4 million and \$3.2 million, respectively. These valuation allowances mostly relate to uncertainties regarding the eventual realization of certain state NOLs. Determination of the amount of deferred tax assets considered realizable requires significant judgment and estimation regarding the forecasts of future taxable income which are consistent with the plans and estimates the Company uses to manage the underlying businesses. Future changes in the estimated realizable portion of deferred tax assets could materially affect the Company's financial condition and results of operations.

*Recent Accounting Pronouncements*

In October 2012, the FASB issued ASU 2012-04, "Technical Corrections and Improvements" ("ASC 2012-04"). The amendments in this update cover a wide range of Topics in the Accounting Standards Codification. These amendments include technical corrections and improvements to the Accounting Standards Codification and conforming amendments related to fair value measurements. The amendments in this guidance that will not have transition guidance are effective upon issuance. The amendments that are subject to transition guidance are effective for fiscal periods beginning after December 15, 2012 and were adopted by the Company during the quarter ended March 31, 2013. The guidance did not impact the Company's consolidated results of operations, financial position, or cash flows.

In February 2013, the FASB issued ASU No. 2013-02, "Comprehensive Income (Topic 220): Reporting of Amounts Reclassified out of Accumulated Comprehensive Income" ("ASU 2013-02"). ASU 2013-02 requires companies to report the effect of significant reclassifications out of accumulated other comprehensive income on the respective line items in net income if the amount being reclassified is required under GAAP to be reclassified in its entirety to net income. Entities are required to provide information about significant reclassifications by component, and to present those reclassifications either on the face of the statement where net income is presented or in the notes. For other amounts that are not required to be reclassified in their entirety to net income, entities are required to cross-reference other disclosures that provide additional details about those amounts. The amendments in this ASU do not change the current requirements for reporting net income or other comprehensive income in financial statements. The amendments in this ASU are effective prospectively for reporting periods beginning after December 15, 2012 and were adopted by the Company during the quarter ended March 31, 2013. The guidance did not impact the Company's consolidated results of operations, financial position, or cash flows.

In July 2013, the FASB issued ASU No. 2013-11, "Income Taxes (Topic 740): Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Carryforward Exists" ("ASU 2013-11"). ASU 2013-11 provides guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, a similar tax loss, or a tax credit carryforward exists. An unrecognized tax benefit should be presented in the financial statements as a reduction to a deferred tax asset for a net operating loss carryforward, a similar tax loss, or a tax credit carryforward with certain exceptions, in which case such an unrecognized tax benefit should be presented in the financial statements as a liability. The amendments in this ASU do not require new recurring disclosures. The amendments in this ASU are effective for reporting periods beginning after December 15, 2013. The guidance is not expected to materially impact the Company's consolidated results of operations, financial position, or cash flows.

Table of Contents

**Item 3. Quantitative and Qualitative Disclosures about Market Risk.**

Changes in interest rates affect interest income earned on the Company's cash equivalents and investments, as well as interest expense on variable interest rate borrowings under the Company's 2011 Credit Facility. Based on the amount of cash equivalents and investments and the borrowing levels under the 2011 Credit Facility as of September 30, 2013, a hypothetical 10 percent increase or decrease in the interest rate associated with these instruments, with all other variables held constant, would not materially affect the Company's future earnings and cash outflows.

**Item 4. Controls and Procedures.**

a) The Company's management evaluated, with the participation of the Company's principal executive and principal financial officers, the effectiveness of the Company's disclosure controls and procedures (as defined in Rules 13a-15(e) under the Exchange Act), as of September 30, 2013. Based on their evaluation, the Company's principal executive and principal financial officers concluded that the Company's disclosure controls and procedures were effective as of September 30, 2013.

b) Under the supervision and with the participation of management, including the Company's principal executive and principal financial officers, the Company has determined that there has been no change in the Company's internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act) that occurred during the Company's quarter ended September 30, 2013 that has materially affected, or is reasonably likely to materially affect, the Company's internal control over financial reporting.

Table of Contents

**PART II OTHER INFORMATION**

**Item 1. Legal Proceedings.**

The management and administration of the delivery of specialty managed healthcare entails significant risks of liability. From time to time, the Company is subject to various actions and claims arising from the acts or omissions of its employees, network providers or other parties. In the normal course of business, the Company receives reports relating to deaths and other serious incidents involving patients whose care is being managed by the Company. Such incidents occasionally give rise to malpractice, professional negligence and other related actions and claims against the Company or its network providers. Many of these actions and claims received by the Company seek substantial damages and therefore require the Company to incur significant fees and costs related to their defense.

On July 25, 2012, the Company filed a lawsuit currently pending in the United States District Court for the District of Connecticut against two former employees and a corporation partially-owned by one of such former employees asserting claims for violation of contractual restrictive covenants and common law obligations owed to the Company arising from actions of such former employees in connection with their employment by the defendant corporation. The Company's complaint alleges claims for breach of contract and breach of the covenant of good dealing against the individual former employees; tortious interference with contract against the defendant corporation; and violation of the Connecticut Uniform Trade Secrets Act, civil conspiracy, and violation of the Connecticut Unfair Trade Practices Act against all defendants arising out of activity undertaken by the former employees on behalf of the defendant corporation in competition with the Company's specialty pharmacy business. The Company is seeking a permanent injunction and recovery of compensatory and punitive damages and an award of attorneys' fees and costs. On December 18, 2012, the defendant corporation filed counterclaims against the Company in which it asserts tortious interference with business expectancy, abuse of process, and violation of the Connecticut Unfair Trade Practices Act arising out of the Company's efforts to enforce its contractual and legal rights. On June 10, 2013, the defendant corporation disclosed an alleged damages computation in the amount of \$155 million in lost profits plus unspecified business diminution damages. The Company believes the counterclaims and damages calculations of the defendant corporation are without merit and is defending them vigorously.

The Company is also subject to or party to certain class actions and other litigation and claims relating to its operations or business practices. In the opinion of management, the Company has recorded reserves that are adequate to cover litigation, claims or assessments that have been or may be asserted against the Company, and for which the outcome is probable and reasonably estimable. Management believes that the resolution of such litigation and claims will not have a material adverse effect on the Company's financial condition or results of operations; however, there can be no assurance in this regard.

**Item 1A. Risk Factors.**

There has been no material change in our risk factors as disclosed in Part I Item 1A "Risk Factors" of the Company's Annual Report on Form 10-K for the year ended December 31, 2012 which was filed with the SEC on February 28, 2013.

**Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.**

The Company's board of directors has previously authorized a series of stock repurchase plans. Stock repurchases for each such plan could be executed through open market repurchases, privately negotiated transactions, accelerated share repurchases or other means. The board of directors authorized management to execute stock repurchase transactions from time to time and in such amounts and via such methods as management deemed appropriate. Each stock repurchase program could be limited or terminated at any time without prior notice.

Table of Contents

On October 25, 2011 the Company's board of directors approved a stock repurchase plan which authorized the Company to purchase up to \$200 million of its outstanding common stock through October 25, 2013. On July 24, 2013 the Company's board of directors approved an increase and extension of the stock repurchase plan which authorizes the Company to purchase up to \$300 million of its outstanding stock through October 25, 2015.

Stock repurchases under the program may be purchased from time to time in open market transactions (including blocks) or in privately negotiated transactions. The timing of repurchases and the actual amount purchased will depend on a variety of factors including the market price of the Company's shares, general market and economic conditions, and other corporate considerations. Repurchases may be made pursuant to plans intended to comply with Rule 10b5-1 under the Securities Exchange Act of 1934, which could allow the Company to purchase its shares during periods when it otherwise might be prevented from doing so under insider trading laws or because of self-imposed trading blackout periods. Repurchases are expected to be funded from working capital and anticipated cash from operations. The repurchase authorization does not require the purchase of a specific number of shares and is subject to suspension or termination by the Company's board of directors at any time. Pursuant to this program, the Company made open market purchases of 671,776 shares of the Company's common stock at an average price of \$48.72 per share for an aggregate cost of \$32.7 million (excluding broker commissions) during the period from November 11, 2011 through December 31, 2011. Pursuant to this program, the Company made open market purchases of 459,252 shares of the Company's common stock at an average price of \$50.27 per share for an aggregate cost of \$23.1 million (excluding broker commissions) during 2012. Pursuant to this program, the Company made open market purchases of 955,776 shares of the Company's common stock at an average price of \$50.23 per share for an aggregate cost of \$48.0 million (excluding broker commissions) during the nine months ended September 30, 2013. As of September 30, 2013, the total dollar value remaining under the current authorization was \$196.2 million. The Company made no open market purchases during the quarter ended September 30, 2013 or for the period from October 1, 2013 through October 21, 2013.

**Item 3. Defaults Upon Senior Securities.**

None.

**Item 4. Mine Safety Disclosures.**

None.

**Item 5. Other Information.**

*Acquisition of Partners Rx Management LLC*

Pursuant to the September 6, 2013 Agreement and Plan of Merger (the "Merger Agreement") with Partners Rx Management, LLC ("Partners Rx"), on October 1, 2013 the Company acquired (the "Acquisition") all of the outstanding ownership interests of Partners Rx. Partners Rx is a privately held, full-service commercial PBM with a strong focus on health plans and self-funded employers primarily through sales through third party administrators ("TPAs"), consultants and brokers. As consideration for the Acquisition, the Company paid \$100 million in cash, subject to working capital adjustments. The Company funded the Acquisition with cash on hand.

Pursuant to the Merger Agreement, certain principal owners of Partners Rx purchased a total of \$10 million in the Company's restricted stock at a price equal to the average of the closing prices of the Company's stock for the five trading day period ended on the day prior to the execution of the Merger Agreement. The shares received by such principal owners of Partners Rx are subject to vesting over three years with 50% vesting on the second anniversary of the Acquisition and 50% vesting on the

Table of Contents

third anniversary of the Acquisition, conditioned on continued employment with the Company on the applicable vesting dates.

The Company will report the results of Partners Rx within its Pharmacy Solutions segment.

*Acquisition of AlphaCare Holdings, Inc.*

The Company holds a 7% equity interest in AlphaCare of New York, Inc. ("AlphaCare") through an equity investment of \$2.0 million in preferred membership units of AlphaCare's current holding company, AlphaCare Holdings, LLC on May 17, 2013. During the current year, the Company also loaned \$5.9 million to AlphaCare Holdings, LLC pursuant to a promissory note (the "Note") which was secured by a pledge of all of the outstanding stock of AlphaCare. AlphaCare is a newly licensed HMO in New York that operates a New York Managed Long-Term Care Plan ("MLTCP") in Bronx, New York, Queens, Kings and Westchester Counties, and Medicare Plans in Bronx, New York, Queens and Kings Counties.

On August 13, 2013, the Company entered into a stock purchase agreement (the "Stock Purchase Agreement") under which it agreed to acquire a 65% equity interest in AlphaCare through an investment in its holding company.

As contemplated by the Stock Purchase Agreement, AlphaCare Holdings, LLC will merge with and into AlphaCare Holdings, Inc. ("AlphaCare Holdings"), a recently-formed Delaware holding corporation, and the Company's 7% equity interest and the Note will be converted into shares of Series A Participating Preferred Stock ("Series A Preferred") of AlphaCare Holdings. The Company will also purchase additional shares of Series A Preferred stock such that it will own 65% of the outstanding shares of AlphaCare Holdings for an aggregate acquisition price of \$25.5 million, including its original investment of \$7.9 million.

The closing of the Stock Purchase Agreement is subject to various conditions, including approval of the New York State Department of Health. The Company expects that the closing of the Stock Purchase Agreement will occur in late 2013 or early 2014.

Table of Contents

**Item 6. Exhibits.**

<b>Exhibit No.</b>	<b>Description</b>
31.1	Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2	Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1	Certification of Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished).
32.2	Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished).
101	The following materials from the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2013 formatted in Extensible Business Reporting Language (XBRL): (i) the Consolidated Statements of Comprehensive Income, (ii) the Consolidated Balance Sheets, (iii) the Consolidated Statements of Cash Flows and (iv) related notes.

